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ABSTRACT
Diabetes is becoming increasingly prevalent in North America, highlighting the
necessity to create a renewable source of pancreatic P-cells for therapeutic purposes. The
current study was undertaken to explore the hypothesis that ectopic expression o f lineage
determining transcription factors could generate a source of proliferative, homogenous
pancreatic progenitor cells capable of subsequent differentiation to functional endocrine
cell types, including P-cells. We validated transgenic systems for transgene delivery in
HE SC and subsequently generated and analyzed gene expression patterns in transgenic
cell populations engineered to constitutively express pancreatic transcription factors
PAX4, PDX1, or NGN3.

We demonstrate that ectopic expression of either PAX4 or

PDX1 is not sufficient to specify pancreatic cells from human embryonic stem cells or
definitive endoderm cells. In contrast, ectopic NGN3 expression specifies pancreatic
endocrine cells from definitive endoderm. In conclusion, this study provides proof of
principle of the ability to generate pancreatic endocrine cells using transcription factor
overexpression in human embryonic stem cells.

Keyword: Diabetes, human embryonic stem cells, transcription factor, SOX17, PDX1,
NGN3, PAX4, differentiation
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1.0 INTRODUCTION
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1.1 Diabetes Mellitus
Diabetes mellitus is a chronic, metabolic disease of insulin insufficiency, affecting
millions of people worldwide. During the disease state, there is a high level of glucose in
the blood that results from the autoimmune destruction of insulin secreting P-cells in the
islets of Langerhans, or from P-cell dysfunction.

As a result of high blood glucose,

patients present with frequent urination, increased thirst and increased hunger. Long-term
effects of diabetes are cardiovascular disease, renal failure, and retinal damage (Group,
1993).

Recently, diabetes mellitus has become more prevalent, with 2.5 million

Canadians having the disease in 2010. This rise in incidence can be attributed to factors
such as increased obesity rates, and high rates of cardiovascular disease (Hotamisligil et
al., 1993).
Despite the prevalence of diabetes, and the large financial burden to society, there
is no renewable source of P-cells for therapeutic replacement. Currently, therapies are
limited to insulin injection regimens

and whole pancreas or pancreatic islet

transplantation; however there is an insufficient source of donor tissue to keep up with
demand for treatment (Bonner-Weir and Weir, 2005; Shapiro et al., 2000). This
insufficient source of donor tissue has stimulated researchers to seek methods to generate
a renewable source of functional P-cells.

1.1.1 Types o f Diabetes Mellitus
There are three predominant types of diabetes: type 1 diabetes, type 2 diabetes,
and gestational diabetes. Type 1 diabetes affects 10% of the diabetic population. This

3
type of diabetes occurs due to a T-cell mediated autoimmune destruction of pancreatic
islet P-cells, leading to insulin insufficiency (Bedossa et al., 1989). Individuals with Type
1 diabetes are commonly diagnosed at an early age with a sudden onset.
Type 2 diabetes is the most common form of the disease, affecting approximately
90% of patients diagnosed with diabetes. Type 2 diabetes is characterized by resistance
to insulin action due to dyslipidemia, and subsequent reduction in insulin secretion with
disease progression (Boden, 1996). This form of diabetes has classically presented in
adults, however there is now an increased prevalence of children and adolescents that are
being diagnosed. The prevalence of type 2 diabetes can be attributed to increased obesity
rates within the population (Hotamisligil et al., 1993).
Gestational diabetes is defined as glucose intolerance with onset or first
recognition during pregnancy (Metzger and Coustan, 1998).

Gestational diabetes is

present in 2 to 5% of pregnant women and is most commonly diagnosed in the third
trimester. If left untreated, gestational diabetes can affect the health of both the mother
and the baby.

Women that have gestational diabetes are at a much higher risk of

developing type 2 diabetes and cardiovascular disease following pregnancy, while their
offspring tend to be large for gestational age and are at a greater risk for developing
childhood obesity and resultant type 2 diabetes (Boney et al., 2005; Carr et al., 2006).

1.1.2 Treatments fo r Diabetes Mellitus
Currently, the predominant therapy for both type 1 and type 2 diabetes mellitus is
insulin injection regimens.

This treatment consists of subcutaneous injections of

4
biosynthetic insulin. There are different types of exogenous insulin: rapid acting, short
acting, intermediate acting, long acting and biphasic acting.

These variations in

exogenous insulin allow for patient-specific insulin injection regimes.

Rapid acting

insulin is used immediately prior to a meal, as it begins to work within 15 minutes. Short
acting insulin is injected up to an hour prior to a meal, and lasts up to 8 hours following
injection. Intermediate acting insulin must be injected at least an hour prior to a meal,
and lasts for up to 16 hours. Intermediate acting insulin is commonly coupled with short
acting insulin for complete daily coverage.

Long acting insulin only requires one

injection per day either in the morning or before bed, as it lasts for up to 24 hours. In
addition to subcutaneous injections, the use of an insulin pump has become common, as it
is capable of providing a constant drip of insulin throughout the day (Group, 1993).
Though proven to be effective, insulin injections are not as sensitive as endogenous
insulin and can result in unfavourable patient outcomes. In addition, patients can still
have episodes of hypoglycemia, which can lead to unconsciousness, seizures, and brain
damage.

Additionally, multiple, daily injections can be a financial burden on the

population.
An alternative to insulin injection regimens is whole pancreas or pancreatic islet
transplantation (Ballinger and Lacy, 1972; Kelly et al., 1967; Shapiro et al., 2000).
Transplantation is an option for therapy, as diabetes affects a single cell type. According
to the Edmonton Protocol developed in 2000, 600,000 islet equivalents or 1 billion P-cells
are required per transplant (Shapiro et al., 2000). The Edmonton Protocol built on these
strategies to optimize islet transplantation in humans. This technique involves the
transplantation of islets into the hepatic portal vein to allow them to lodge in a safe area.
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Patients undergoing transplantation require constant immunosuppression to prevent
immune rejection.

Unfortunately, longitudinal studies concluded that only 10% of

patients were insulin independent 5 years following their initial transplant (Ryan et ah,
2005). Approximately 80% of patients had islet graft survival at this point, however most
demonstrated impaired function.

This outcome has been postulated to be due to the

inflammatory response that occurs

immediately after transplantation, continued

autoimmune destruction, in addition to the immunosuppressive drugs which are toxic to
P-cells at high concentrations (Bell et ah, 2003; Moberg et al., 2002; Ryan et al., 2005).
At the moment, the greatest limitation to this therapy is availability of donor tissues for
transplantation.

However, the Edmonton Protocol provides the proof-of-principle that

cell based therapy can effectively restore insulin-independence in patients (Shapiro et al.,
2000).

1.2 Pancreatic Development
The mature pancreas is comprised of an exocrine compartment and an endocrine
compartment (Figure 1.1). The exocrine compartment of the pancreas constitutes 98% of
the total area and is made up of ductal and acinar cells that are responsible for secreting
enzymes such as trypsinogen, chemotrypsin and pancreatic amylase to allow for digestion
of carbohydrates, proteins and fatty acids (Rutter et ah, 1968). Conversely, the endocrine
compartment of the pancreas constitutes 2% of the total area and is comprised of
functional units called the islets of Langerhans. Once the pancreas is formed, it is limited

6

Figure 1.1 The pancreas is comprised of both exocrine and endocrine compartments
(A) The endocrine compartment of the pancreas is composed of structures termed the islets
of Langerhans. These islets are comprised of 5 cell types, each of which secretes a specific
endocrine hormone.

The a-cell secretes glucagon, the P-cell secretes insulin, the 8-cell

secretes somatostatin, the e-cell secretes ghrelin, and the PP cell secretes pancreatic
polypeptide. Cells are aggregated around capillaries, which allow for the hormones to enter
the vasculature and act on target tissues. (B) The exocrine compartment of the pancreas is
composed of pancreatic acinar cells and ductal cells. Acinar cells secrete enzymes necessary
A
for digestion, while ductal cells provide the ducts for these enzymes to travel through.
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in its ability to regenerate, as there is a restricted pool of progenitor cells that do not
readily differentiate upon pancreatic cell loss (Stanger et al., 2007).
Pancreatic development begins at day 26 of human gestation when the definitive
endoderm germ layer (DE), the layer that forms the embryonic gut and associated organs
such as liver, lungs, and pancreas, evaginates into the surrounding mesenchyme, forming
the dorsal pancreatic bud (Amit et al., 2000) (Figure 1.2). The ventral pancreatic bud
arises from the caudal aspect of the hepatic/biliary bud by a similar mechanism six days
later (Pictet et al., 1972). After both pancreatic buds have emerged, basal regions of each
bud begin to elongate, forming stalks. Meanwhile, the apical region of each bud begins to
branch at acute angles. Between day 37 and 42, the ventral and dorsal buds come into
contact with each other due to gut rotation, resulting in the fusion of the ventral bud duct
with the distal portion of the dorsal bud duct, forming the duct of Wirsung.

The

remaining portion of the dorsal bud duct is termed the duct of Santorini (Pictet et al.,
1972).
At day 40 to 60 of human gestation, or E13.0-14.0 in the mouse, there is a change
in the cellular composition of the pancreas in what is known as the secondary transition.
Prior to the secondary transition, the pancreas is comprised of predominantly immature acells (Pictet et al., 1972).

During the secondary transition, there is a change in cell

architecture due to expansion of endocrine cell numbers concurrent with exocrine acinar
cell differentiation. The new endocrine cells assemble in a linear pattern along the ducts.
Shortly after birth, the newly formed endocrine cells aggregate to form the islets of
Langerhans (Pictet et al., 1972).

Figure 1.2: Schematic Representation of Pancreatic Development
(A) In humans, at 26 days of gestation, pancreatic buds are formed on both the dorsal and
ventral aspect of the gut tube. (B) This occurs when the definitive endoderm evaginates
into the surrounding mesenchyme. (C-D) Following bud formation, branching and
elongation begins, with the dorsal bud forming a larger structure than the ventral bud. By
day 42, the ventral and dorsal buds fuse due to gut rotation. (E) This fusion generates the
duct of Wirsung, and the accessory duct o f Santorini.
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1.2.1 Pancreatic Endocrine Cells
Within the islets of Langerhans, there are five endocrine cell types. The most
predominant endocrine cell type, comprising 65-80% of the islets of Langerhans, is the Pcell (Pictet et al., 1972). In response to high blood glucose concentrations, glucose enters
the p-cells through the GLUT2 glucose transporter and is metabolized to ATP.

The

resultant ATP induces p-cell membrane depolarization and insulin release. The insulin
hormone then enters the circulation and eventually binds the insulin receptor on
hepatocytes and myocytes, promoting the uptake of glucose, which is stored as glycogen
in the liver and skeletal muscle. After insulin receptor binding, insulin is either released
and able to act on other insulin receptors, or is degraded and cleared through the liver or
kidney (Duckworth et al., 1998). P-cells also secrete C-peptide, a byproduct of insulin
biosynthesis. To form mature insulin, proinsulin is cleaved by prohormone convertases 1
and 2, excising C-peptide from the center of the proinsulin peptide. The resultant insulin
peptide fragments are then joined by disulfide bonds, forming insulin (Steiner and Oyer,
1967). In rodents, P-cells are localized to the center of the islets of Langerhans, while in
humans, p-cells are dispersed randomly throughout the islets.
The second most predominant endocrine cell type in the adult pancreas is the
glucagon-secreting a-cell, comprising between 10-15% of the endocrine compartment
(Pictet et al., 1972). In response to low blood glucose, a-cells secrete glucagon, a peptide
hormone that acts on hepatocytes to promote glycogenolysis.
increased blood glucose levels.

The resultant effect is

In rodents, a-cells are localized to the outside of the

islets, while in humans, a-cells are dispersed throughout the islets.
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The third most abundant endocrine cell type, comprising 3-10% of the pancreas is
the 8-cell. Delta cells secrete the peptide hormone somatostatin. The role of somatostatin
within the endocrine pancreas is to inhibit the release of insulin and glucagon. In rodents,
8-cells are located at the periphery of the islet, while they are dispersed throughout in
humans. Approximately 3-5% of the endocrine pancreas is comprised of PP cell that
secrete pancreatic polypeptide. Pancreatic polypeptide (PP) is responsible for regulating
hepatic glycogen levels by altering the insulin receptor found on the membrane of hepatic
cells. In response to hypoglycemia, PP is released to promote glycogenolysis. Lastly, scells comprise less than 1% of the endocrine compartment of the pancreas. Epsilon cells
are responsible for secreting ghrelin, a hormone responsible for stimulating the feeling of
hunger by acting on the hypothalamus (Klok et al., 2007).

1.2.2 Growth Factor Signaling Pathways in Pancreatic Development
During pancreatic development, there are many signaling pathways that are
required for proper organ patterning.

Wnt signaling is an important, and temporally

regulated process required for the formation of the pancreatic endoderm.

Generally,

Wnt3a is localized within the pancreatic mesenchyme, with overexpression leading to
pancreatic hypoplasia affecting the islets of Langerhans, as well as pancreatic acinar cells
(Heller et ah, 2002).
Mammalian transforming growth factor (TGF) -p i, -P2, and -P3 are detected in
the developing pancreatic epithelium at E l2.5 in the mouse, and later co-localize within
acinar cells (Crisera et ah, 1999).

By E18.5, these TGF-P isoforms are specific to
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pancreatic ducts, concurrent with expression of TGF-|3 receptor type I and type II
(Tulachan et al., 2007).

Transgenic mice expressing TGF-pi under the rat insulin

promoter have shown that TGF-(3 signaling is required for the ability of endocrine cells to
form islets in the mouse pancreas (Lee et al., 1995; Sanvito et al., 1995). Inhibition of
TGF-P signaling in mice through a dominant-negative form of TGF-P receptor type II
results in ductal hyperplasia and acinar atypia (Bottinger et al., 1997). Taken together,
TGF-P signaling is required to recruit duct cells to the endocrine lineage.
Activin signaling is required to specify definitive endoderm, as well as distinct
stages throughout pancreatic development for proper patterning, but fine control of this
pathway is essential. The notochord is a structure that forms during gastrulation and is
responsible for patterning the axis of the developing embryo. The pancreas is situated
adjacent to the notochord during development. In order for proper pancreas formation,
sonic hedgehog (SHH) must be inhibited in the endoderm of the pancreatic region of the
gut tube. The notochord secrets activins, which are inhibitors of SHH, resulting in areas
of the gut tube that are capable of undergoing pancreatic bud formation (Hebrok et al.,
1998).

In chick embryos, the removal of the notochord results in the absence of

pancreatic gene expression (Kim et al., 1997; Melton et al., 1998). Activin A and B are
expressed in developing rat and mouse pancreatic endocrine cells, especially a-cells
(Furukawa et al., 1995; Maldonado et al., 2000). The addition of exogenous activin A to
monolayer cultures of human fetal pancreas cells, results in increased number of insulin
positive cells and subsequent increases in insulin content (Demeterco et al., 2000).
Conversely, inhibition of activin by follistatin, which is found within the pancreatic
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mesenchyme, results in exocrine differentiation (Miralles et al., 1998). These studies
suggest that activin A is required for the differentiation of pancreatic endocrine cells.
Fibroblast growth factors (FGFs) play an important role in branching
morphogenesis of the developing pancreas (Hogan, 1999). FGF10 expressed in the
mesenchyme is required for proper pancreatic formation by controling mesenchymal-toepithelial signaling. Mice lacking FGF10 have restricted pancreatic growth (Bhushan et
al., 2001). Conversely, ectopic expression of FgflO in vivo under the control of the Pdxl
promoter in mice results in increased proliferation of the pancreas at the expense of cell
differentiation, as cells maintained a pancreatic progenitor phenotype and were unable to
undergo terminal differentiation (Edlund et al., 2003). It is believed that FGF signaling in
the pancreas is mediated by Notch signaling. This has been shown in studies where
overexpresion of FGF 10 in transgenic mice results in the maintenance of Notch pathway
activation, preventing pancreatic progenitor differentiation (Norgaard et al., 2003). In the
pancreas, inhibition of Notch signaling results in robust commitment of cells to the
endocrine lineage (Edlund et al., 1999).

1.3 Pancreatic Transcription Factors

1.3A SOX17
Sry-related HMG box genes encode a family of transcription factors that possess a
highly conserved high mobility group (HMG) responsible for DNA binding in the minor
groove (Schepers et al., 2002; Wegner, 1999). This HMG box was originally identified in
SRY, the sex determining gene on the Y chromosome. In general, SOX transcription
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factors have weak binding specificity in addition to low affinity for DNA (Wegner,
1999). Sox transcription factors are encoded by 20 genes in human and mouse.
Sry-related HMG-box 17 (SOX17) is a 414aa transcription factor that plays a role
in embryonic development and cell fate determination through the regulation of Wnt3a
signaling (Figure 1.3 A). SOX17 is classified into the F group of SOX genes along with
SOX7 and SOX 18, transcription factors that share similarity outside the DNA-binding
domain (Dunn et al., 1995; Schepers et al., 2002; Taniguchi et al., 1999). Importantly,
S o xl7 has been found to play an essential role in endoderm differentiation: it is expressed
concurrent with DE formation and is downregulated upon DE specification (KanaiAzuma et al., 2002).

Soxl7 null mice are embryonic lethal, due to apoptosis of the

foregut endoderm and failure of mid- and hindgut expansion.
S o xl7

Using chimera assays,

embryonic stem (ES) cells were shown to contribute to all aspects of gut DE,

however they undergo incrased apoptosis in the foregut, and fail to differentiate in the
posterior regions (Kanai-Azuma et al., 2002).

1.3.2 PDX1
Pancreatic and duodenal homeobox gene 1 (PDX1) is a 283aa transcription factor
that regulates the expression of insulin, somatostatin, islet amyloid polypeptide,
glucokinase, Glut2 as well as itself (Figure 1.3 B) (Hui and Perfetti, 2002). In mice and
humans, all pancreatic endocrine and exocrine cells are derived from PDX1 positive
progenitors (Gu et al., 2003).

PDX1 is characterized by a central DNA binding

homeodomain that possesss a signal for nuclear localization (Hessabi et al., 1999), Lu

Figure 1.3: Pancreatic Transcription Factor Structures
Schematic representation of pancreatic transcription factor structures. (A) SOX 17 has a
SOX HMG box domain at the N-terminus of the transcription factor. (B) PDX1 contains
a transactivation domain at the N-terminal of the protein, a homeodomain that includes a
nuclear localization signal in the center of the protein, and a phosphorylation site at the Cterminus. (C) NGN3 belongs to the basic helix-loop-helix family of transcription factors
that contain a helix-loop-helix domain in the center of the protein. (D) PAX4 has a paired
box domain at the N-terminus of the protein, in addition to a homeodomain that is found
in the center of the protein.
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1996). The N-terminus of PDX1 contains a transactivation domain that allows the protein
to interact with other transcription factors and transcriptional co-regulators such as
hepatocyte nuclear factor 6 (HNF6), SOX9, hepatocyte nuclear factor 1 homeobox B
(HNF1P), and forkhead box A2 (FOXA2) (Mosley and Ozcan, 2004; Oliver-Krasinski et
al., 2009).

Additionally, there is a proline-rich domain situated in the middle of the

protein that has been shown to be involved in heterodimerization with the DNA binding
protein Pre B-cell leukemia transcription factor (PBX1) and varying additional binding
partners to form a transcriptional regulatory complex (Goudet et al., 1999).

The C-

terminus of PDX1 is not essential for DNA binding, however it is necessary for the
activation of target gene promoters either by direct interaction, or by changing the
conformation of other interacting regions (Oliver-Krasinski et al., 2009; Peers et al.,
1994). There are many islet transcription factors such as Pax6, MafA and FoxA2 that
bind to PDX1 and activate it through conserved cis-acting elements between 1923bp and
2153bp.

In addition, Pdxl binds to and regulates several promoters for downstream

genes such as Nkx6.1 and Pax6 as well as preproinsulin (Svensson et al., 2007).
In the mouse, expression of Pdxl is restricted to the developing pancreas
following pancreatic specification of the foregut endoderm. By E10.5, Pdxl expression is
downregulated throughout the pancreatic compartment and remains low until E l 3.0 when
it is upregulated upon (3-cell differentiation (Ohlsson et al., 1993). Pdxl expression is
maintained in adult P-cells (Ahlgren et al., 1998). Additionally, Pdxl is expressed in
other tissues such as the skin (Mazur et al., 2010). Pdxl null mice, as well as mice
homozygous for a targeted deletion of the homeodomain encoding exon 2 of the Pdxl
gene lack a pancreas and consequently, die within a few days of birth (Ahlgren et al.,
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1996; Jonsson et al., 1994). Pdxl haploinsufficient mice have smaller islets that contain
fewer (3-cells, leading to decreased insulin secretion and glucose intolerance that
ultimately results in diabetes (Offield et al., 1996). In humans, a mutation at amino acid
178, located within the second helix of the homeodomain, results in neonatal diabetes
with subclinical exocrine deficiency (Nicolino et al., 2010), while a homozygous
frameshift mutation at amino acid 63 prevents translation of the homeodomain as well as
the C-terminus, thereby causing pancreatic agenesis (Stoffers et al., 1997). Individuals
that are heterozygous for PDX1 mutations associated with neonatal diabetes will later
develop maturity onset diabetes of the young 4 (MODY4) (Nicolino et al., 2010).
Given its function during pancreatic development, several studies have tested the
ability of Pdxl expression to induce endocrine differentiation.

Mouse ES cells with

ectopic tet-inducible Pdxl gene expression have been differentiated following a 5 step
pancreatic differentiation protocol. At the end of the differentiation process, these cells
express somatostatin, insulin2, Nkx2.2, Pax4, Pax6 and Ngn3. Though these cells were cpeptide positive, they did not secrete insulin in response to glucose stimulation (Miyazaki
et al., 2004). In contrast, rat small hepatocytes can successfully be differentiated into
insulin-producing cells through overexpression of Pdxl by adenovirus transfection.
These cells also expressed pancreatic markers Ngn3, Pax6, Nkx2.2 and Nkx6.1.
Unfortunately, small hepatocytes, the progenitor cell type in the liver, are difficult to
isolate from the liver, and functional analyses have not been performed on these cells
(Kawasaki et al., 2008).

Stable PDX1 overexpressing telomerase-immortalized bone

marrow derived mesenchymal stromal cells have also been generated. These cells
demonstrate pancreatic gene expression and insulin promoter activity. However, these
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cells were heterogeneous when stained for insulin and c-peptide, and did not respond to
glucose at a biologically relevant level (Limbert et al., 2011).

1.3.3 NGN3
Neurogenin 3 (NGN3) is a 214aa basic helix loop helix transcription factor
necessary for the development of hormone-producing islets (Figure 1.3C). In the
developing mouse pancreas, Ngn3 expression is initiated at E8.5 in the dorsal pancreatic
bud, while expression begins at E9.5 in the ventral pancreas.

From E9.5 to E12.5,

expression of Ngn3 is localized to the pancreatic endoderm where it is maintained until
birth, and subsequently downregulated due to auto-repression (Gradwohl et al., 2000;
Smith et al., 2004).

In addition to pancreatic expression, Ngn3 is expressed in the

developing and mature hippocampus (Simon-Areces et al., 2010), as well as neuronal
progenitor cells from E9.0 to E14.0 (Lee et al., 2001; Sommer et al., 1996).

Ngn3

positive cells give rise to pancreatic endocrine cells that express endocrine transcription
factors such as Nkx6.1 and Pax6 (Jensen et al., 2000; Smith et al., 2004). It has been
found that Ngn3 binds to promoters of NeuroD, Pax4 and insulinoma associated antigen 1
(I a l) (Huang et al., 2000; Smith et al., 2003).
Mice lacking Ngn3 lack the endocrine component of the pancreas, leaving an
exocrine compartment that contains few glucagon expressing cells. These mice develop
diabetes due to a lack of P-cells and die between 1 and 3 days after birth (Gradwohl et al.,
2000). Ectopic expression of Ngn3 in pancreatic ductal cells in vivo using an adenovirus
results in the expression of endocrine specific genes, however this starting population is
limited (Gasa et al., 2004). Ectopic NGN3 expression in human pancreatic ductal cells
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produces insulin positive cells, however this occurs in only 13% of the cells (Heremans et
al., 2002).

In contrast, in ovo electroporation of Ngn3 in chick embryos results in

glucagon and somatostatin producing cells, however no insulin or c-peptide positive cells
were reported (Grapin-Botton et al., 2001). Ectopic expression of Ngn3 in conjuction
with Pdxl in mouse ES cell-derived endoderm generates insulin and c-peptide positive
cells, however these cells are not responsive to glucose (Kubo et al., 2011).
Overexpression of Ngn3, MafA, and Pdxl is capable of transdifferentiating pancreatic
acinar cells into insulin positive cells in vivo, however this strategy is only 20% efficient
and has a limited starting population (Zhou et al., 2008).

1.3.4 PAX4
Paired box gene 4 (PAX4) is a 343aa nuclear transcription factor that is localized
to the endocrine pancreas during embryonic development (Figure 1.3 D) (Sosa-Pineda et
al., 1997). PAX genes encode regulators of embryonic organ development (Mansourie et
al., 1996) and are characterized by a domain consisting of a highly conserved 128 amino
acid motif that possesses DNA binding activities (Noll 1993). In particular, Pax4 and
Pax6 share a homeodomain, as well as a highly conserved octapeptide (Dahl et al., 1997).
Expression of Pax4 begins at E 10 in a small number of cells in the pancreatic bud (SosaPineda et al., 1997). By E14.5, there is a significant increase in Pax4 positive cells in the
dorsal pancreas, and by E15.5 the number of Pax4 expressing cells reaches its maximum
(Dohrmann et al., 2000; Sosa-Pineda et al., 1997). Pax4 is not expressed in any exocrine
cell type (Sander 1997, St Onge 1997). Pax4 is directly regulated by Ngn3, and serves to
regulate expression of downstream targets including Nkx6.1 (Smith et al., 2003; Tang et
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al., 2006). It has been shown that Pax4 is required to maintain proliferation and survival
of pancreatic P-cells (Brun et al., 2004).
At birth, Pax4 null mice have a normal pancreas with respect to size and weight;
however, the pancreas lacks insulin-secreting (3- and somatostatin-secreting 5- cells. To
compensate for the lack of P and 8 cells, there is an overabundance of a cells that are
situated within the centre of an islet-like structure. Homozygous / >ax4-deficient mice die
3-5 days after birth due to hyperglycemia (Sosa-Pineda et al., 1997). Overexpression of
PAX4 in HESC following embryoid body-mediated definitive endoderm differentiation
produces cells that exhibit functional properties that are typical of P-cells. These cells
comprise 90% of the resultant cell population (Liew et al., 2008). Transgenic mice that
express Pax4 in the pancreatic endocrine tissue, or pancreatic epithelium die between 3
and 12 weeks after birth due to hyperglycemia.

These mice had enlarged islets that

contained mostly P-cells, as ectopic Pax4 expression converted a-cell progenitors to Pcell progenitors (Collombat et al., 2009).

1.3.5 Additional Pancreatic Transcription Factors
V-Maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA) is a
transcription factor required for functional glucose-stimulated insulin secretion in the
pancreas (Kataoka et al., 2002). In the pancreas, Maf proteins function by interacting
with other bZip proteins, which are transcription factors that contain basic leucine zipper
domains, forming heterodimers (Igarashi et al., 1994) that bind to the RIPE3bl element in
the promoter of genes such as insulin (Kataoka et al., 2002).

During development,
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expression of MafA is restricted to developing insulin positive cells, and is responsible for
tissue specific insulin expression (Matsuoka et al., 2004). MafA is initially detected at
E l3.5 in mice, during the secondary transition of pancreatic development (Matsuoka et
al., 2004). Conversely, MafB is present in developing a- and P-cells (Artner et al., 2006),
but is restricted to a-cells following birth (Nishimuro 2006). In the development of the
pancreatic p-cell, there is a transition between MafB expression and MafA expression that
is required for proper glucose stimulated insulin secretion. Cells that are MafB positive
and insulin positive are not functional until they are MafA positive and insulin positive
(Kroon et al., 2008). MafA'1' mice have normal islet architecture at birth, however by 12
weeks of age, there is a change in the composition of pancreatic islets with an increase the
ratio of a- to P-cells. Consequently, MafA'1' mice develop overt diabetes mellitus (Zhang
et al., 2005). Overexpression of MafA in conjunction with Pdxl and NeuroDl can induce
the expression of endogenous insulin in the liver (Kaneto et al., 2005). Alternatively,
overexpressing MafA concurrently with Pdxl and Ngn3 is capable of transdifferentiating
pancreatic acinar cells into insulin positive cells (Zhou et al., 2008).

In ovo

electroporation of MafA in embryonic chick endoderm lead to the formation of insulin
positive cells (Artner et al., 2008). Human placenta derived multipotent stem cells that
overexpress MAFA were assessed by microarray analysis and were found to exhibit a
gene expression profile consistent with pancreatic islets. Additionally, these cells were
responsive to glucose and corrected hyperglycemia in immunocompromised mice that
had streptozotocin-induced diabetes. A downfall to these cells is that they co-express
glucagon and insulin (Chiou et al., 2011).
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1.4 Human Embryonic Stem Cells
Human embryonic stem cells (HESC) are derived from the inner cell mass of the
blastocyst, which is formed 4-5 days following fertilization.

If maintained in the

appropriate medium, containing basic fibroblast growth factor, HESC remain pluripotent
and have the potential to form all 220 cell types of the body, including pancreatic P-cells
(Thomson et al., 1998; Xu et al., 2005). Traditionally, HESC are cultured on mouse
embryonic fibroblasts (MEFs) or in the presence of MEF-conditioned media. HESC have
high levels of telomerase activity, allowing these cells to replicate indefinitely (Harley et
al., 1992). HESC are characterized by the expression of the cell surface glycoproteins
stage-specific embryonic antigen (SSEA)3 , SSEA4, TRA-1-60 and TRA-1-81, in
addition to being alkaline phosphatase positive (Thomson et al., 1998). Additionally,
given their pluripotent nature, HESC can produce cancerous and non-cancerous tumours
called teratomas that contain tissues from each primary germ layer when injected into
severe combined immunodeficient (SCID) mice.
Undifferentiated HESC have a distinct, unique morphology characterized by
tightly packed colonies with no observable cell boundaries. The cells possess a high
nuclear to cytoplasmic ratio with prominent nucleoli (Thomson et al., 1998). HESC are
capable of spontaneous differentiation to all cell types, with first indication of HESC
differentiation being change in cell morphology (Imreh et al., 2006).
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1.4.1 Differentiation Strategies to Generate (3-Cells from Human Embryonic Stem Cells
Several strategies have been developed for the generation of (3-cells from
pluripotent HESC. Growth factor-mediated approaches have yielded stepwise protocols
to generate a population of pancreatic-like cells (D'Amour et al., 2005; D'Amour et al.,
2006; Jiang et al., 2007a; Jiang et al., 2007b; Shim et al., 2007). Although these methods
have been extensively characterized, they have limitations that are undesirable.
Specification of DE using Activin A results in a heterogeneous, non-proliferative
population of cells, thereby limiting the population that can further differentiate into
pancreatic cell types. Additionally, these protocols produce a population of cells in which
the (3-cell phenotype comprises less than 15% of the final population.

Furthermore,

transplantation of these (3-cells in mice does not generate functional cells in vivo, and the
mice formed teratomas (D'Amour et al., 2005). Recent studies have optimized growth
factor-mediated approaches by extending activin A treatment to specify DE, followed by
inhibition of activin A, nodal, BMP and TGF-P following pancreatic progenitor formation
in (3-cell development, however resultant populations contain only 25% C-peptide
positive cells (Nostro et al., 2011). These limitations have given rise to a need for a
method to generate a homogenous population of pancreatic endocrine precursors that
maintain a replicative capacity enabling the cell expansion required for eventual cellbased therapies.
1.4.2 Transgenic Strategies fo r Pancreatic Development from HESC
Pancreatic exocrine cells have been transdifferentiated into pancreatic endocrine
cells by in vivo viral-mediated gene delivery of the transcription factors Mafa, Pdxl and
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Ngn3. The initial population of pancreatic exocrine cells is not self-renewable and the
efficiency of transdifferentiation is very low (Zhou et al., 2008).

1.4.2 Genetic Manipulation o f Human Embryonic Stem Cells

1.4.2.1 ER12 System
T2

The estrogen receptor ligand binding domain (ER ) has been used to
to generate transgenes that are constitutively expressed but active only after the addition
of 4-OH Tamoxifen to culture media (Hayashi and McMahon, 2002). This inducible
construct allows for the control of the duration of transcription factor activity, which is
beneficial when mimicking its developmental pattern of activity. The addition of 4-OH
Tamoxifen allows the fusion protein to translocate into the nucleus, enabling it to bind
DNA and regulate transcription (Figure 1.4).
1.4.2.2 piggyBac System
The piggyBac (PB) transposase system is a non-viral vector system that uses the
transient expression of a transposase enzyme and two inverted terminal repeats flanking
the gene of interest to insert transgenes into the host genome at any TTAA site (Figure
1.5).

This system is the most efficient transposon system characterized for use in

mammalian cells and is unique in that transgenes can be removed leaving no genetic
footprint behind using transient expression of PB transposase.

The PB-TET system

allows the gene of interest to be turned on/off by the addition/removal of doxycycline,
which acts through the tet02 promoter. PB-TET is co-electroporated with the PB

Figure 1.4: ERT2 System for Inducible Gene Delivery
(A) The ERt2 system allows for a gene o f interest, fused in frame to the estrogen receptor
ligand binding domain (ERT2), to be constitutively expressed and held at the cytoplasmic
membrane.

(B) Following the addition of 4-OH Tamoxifen, an estrogen analog that

shows a higher affinity for the mutated ERT2 receptor, the fusion protein translocates into
the nucleus where it can become active.

Figure 1.5 Transposon Based Tools for Inducible Transcription Factor Expression
in HESC
(A) The tet02 piggyBac transposase system allows for the gene of interest (GOI), which
is cloned into the PB-TET plasmid and flanked by inverted terminal repeats (ITR), to
jump into the genome following transient expression of the piggyBac transposase
enzyme.

Entry occurs at TTAA sites and transgenic clonal populations selected for

blasticidin resistance. (B) Transcription o f the DNA of interest is induced by the addition
of doxycycline to the culture media, which binds the reverse tetracycline transactivator
(rtTA) protein, allowing it to bind the tet operator and initiate transcription. (Obtained by
MTA from Dr. A. Nagy, Mount Sinai Hospital, Toronto). IRES - Independent ribosomal
entry site, Bgeo -

P-galactosidase/neomycin resistance

fusion gene, polyA -

polyadenylation tail, CAG - CMV enhancer combined with chicken P-actin promoter,
EM7 - promoter for expression of blasticidin resistance.
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transposase plasmid containing the functional transposase enzyme that permits the
integration of PB-TET and CAG-rtTA-blasticidin plasmids into the genome, which
contains the reverse tetracycline transactivator necessary for transcription of the gene of
interest. When bound by doxycycline, the rtTA protein acts on the tet02 promoter to
drive transcription of the gene of interest (Cadinanos and Bradley, 2007; Ding et al.,
2005; Wang et al., 2008). Previous studies have used this method of gene delivery for the
expression of c-Myc, Klf4, Sox2 and Oct4 in mouse fibroblasts and reported functional
transcription factor activities (Woltjen et al., 2009).
1.5 Rationale
Diabetes is becoming increasingly prevalent in North America. Currently the only
treatment options are insulin injection reginmens, or whole pancreas and pancreatic islet
transplantation.

Unfortunately, there is a scarce source of donor tissues for

transplantation, as each transplant requires approximately 1 billion P-cells according to
the Edmonton Protocol.

This project will assay the ability of three independent

transcription factors (PDX1, NGN3, PAX4) to specify a pancreatic endocrine phenotype
following ectopic expression in HESC-derived definitive endoderm.

Additionally, to

better recapitulate the transient and/or biphasic patterns of transcription factor expression
during development, cells with inducible, sequential activation of lineage-determining
transcription factors will be generated to better recapitulate developmental patterns.
1.6 Hypothesis
Following SOX17-mediated definitive endoderm specification, expression of pancreasspecific transcription factors (PAX4, PDX1 or NGN3) will specify pancreatic endocrine
progenitors from human embryonic stem cells.
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1.7 Objectives
The specific objectives of this research project are to:
1. Use constitutive SOX17 expressing HESC to screen for the ability of PAX4,
PDX1 or NGN3 to specify pancreatic endocrine progenitors from definitive
endoderm
2. Characterize definitive endoderm differentiation using transient activation of
SOX17
3. Generate transgenic HESC for transient activation of SOX 17 to specify definitive
endoderm, followed by PAX4, PDX1 or NGN3 to specify pancreatic endocrine
cells

2.0 MATERIALS AND METHODS
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2.1 Cell Culture
CA1 and CA2 (O'Connor et al., 2008; Peerani et al., 2007), as well as CA2 pClip
CAG-Fl-Pgeo-Fl-SOX 17-IRES-PURO (Seguin et al., 2008) and CA1 CAG-SOX17ER^-PURO human embryonic stem cells (HESC) were maintained using conditions
modified from established protocols for HESC derivation and culture (Thomson et al.,
1998). Briefly, cells were grown on mitotically inactivated mouse embryonic fibroblast
feeders (SickKids ESC Facility) in knockout Dulbecco’s Modified Eagle Medium
(DMEM) (Invitrogen) with 15% serum replacement, glutamax, penicillin/streptomycin,
ImM

nonessential

amino acids, 0.5mM mercaptoethanol

and

lOng/mL FGF2.

Transgenic cell populations were selected for by culturing in media supplemented with
the appropriate antibiotic (0.6pg/mL puromycin, 1.0pg/mL G418). When cultures had
attained 75% confluence, cells were passaged by enzymatic dissociation (0.05% TrypsinEDTA), pelleted at 244 rcf/g for 3 minutes and split at a ratio of 1:9 (every 4-6 days).

2.2 Plasmid Construction
The open reading frame (ORF) corresponding to the human NGN3 gene was
amplified by PCR from cDNA that was previously generated in our laboratory from
HESC that were engineered to constitutively overexpress SOX 17 and underwent a
pancreatic growth factor differentiation protocol, resulting in a population containing
insulin-positive cells (Seguin et al., 2008). The sequence corresponding to the PAX4
ORF was amplified by PCR from the full-length cDNA clone ID# HsCD00079789
(Arizona State University).

Both genes were amplified using primers designed to

incorporate 5’Xhol and 3’Notl restriction enzyme sites to allow for directional cloning
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into the expression vector. The resultant amplicons were introduced into the pGEM-T
vector by TA cloning. NGN3, and PAX4 ORFs were introduced independently into the
CAG-MCS-IRES-NEO plasmid containing a CAG promoter (CMV enhancer combined
with chicken [3-actin promoter), a multiple cloning site (MCS), an independent ribosomal
entry site (IRES) and a neomycin-polyA cassette (Figure 2.1) (generously provided by
Dr. H Niwa, RIKEN Center for Developmental Biology).

This construct confers

constitutive expression of the gene of interest in addition to a neomycin resistance gene.
To confirm correct integration and gene sequence, the MCS of the resultant plasmid was
sequenced.
A PB-TET-PDX1 plasmid was generated through a Gateway cloning LR reaction
using lOOng of the mammalian gene collection full-length cDNA clone ID# 40080648
(Invitrogen) PDXl-pDONR223.1,

150ng PB-TET plasmid,

5X LR Clonase II

(Invitrogen), and TE buffer. Gateway cloning is a highly efficient method that uses sitespecific recombination to move DNA sequences into vectors. The LR reaction allows a
donor vector containing attL sites flanking the gene of interest to recombine with a
destination vector containing attR sites flanking a ccdb sequence. The reaction mix was
incubated at 37°C overnight and lpL transformed into 50pL of One Shot OmniMAX 2T1
Phage-Resistant Cells (Invitrogen).

Clonal populations were picked after ampicillin

selection. Purified plasmids were sequence verified.
To visualize the activity of the PB-TET system, through green fluorescent protein
(GFP), a PB-TET-GFP plasmid was obtained from Dr. Janet Rossant at the Hospital for
Sick Children.

Figure 2.1: Schematic representation of construction of plasmids for constitutive
transcription factor expression in HESC
(A) The open reading frames (ORF) for NGN3 and PAX4 were amplified using primers
designed to incorporate Xhol and N otl restriction sites for directional cloning. (B) The
CAG-GFP-IRES-NEOR-PolyA plasmid was digested using Xhol and N otl to excise
GFP. This plasmid contains a CAG promoter (CMV enhancer combined with chicken pactin promoter), GFP (green fluorescent protein), 1RES (independent ribosomal entry
site), NEO r (neomycin resistance gene), polyA (polyadenylated tail).

(C) NGN3 and

PAX4 ORFs were independently cloned into the CAG-IRES-NEO r plasmid.
resultant plasmids were sequence verified.

The
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2.3 Generation of Transgenic HESC
To generate DE cells, CA2 HESC that contained a single integration of the pClip
CAG-Fl-Pgeo-Fl-SOX17-IRES-PURO plasmid were used (Seguin et al., 2008).

This

plasmid contains a CAG promoter (CMV enhancer combined with chicken P-actin
promoter), a floxed Pgeo element (P-galactosidase/neomycin resistance fusion protein),
the SOX17 ORF, an independent ribosomal entry site (IRES), and the puromycin
resistance gene.

These cells remain undifferentiated in culture, and are induced to

express SOX 17 following the introduction of Cre recombinase. The overexpression of
SOX17 drives these HESC to a DE fate.

To induce SOX17 expression, three confluent

wells of a 6 well dish were enzymatically dissociated into single cells (0.05% TrypsinEDTA) and centrifuged at 244 rcf/g for three minutes.

The resultant cell pellet was

resuspended in 400pL electroporation buffer (Gibco) and added to a 4mm electroporation
cuvette containing 20pg of CAG-NLS-CRE plasmid.

This plasmid contains a CAG

promoter, a nuclear localization sequence (NLS) and the ORF for Cre recombinase. The
electroporation cuvette was inserted into an electroporator (BioRad) and pulsed at 170V,
1050pF.

Cells were then plated into a 6 well plate, and after 48 hours, transgene

expression was selected for using 0.6pg/mL puromycin.
HESC were previously generated in the lab that allow for control of dose and
duration of SOX17 expression. CA1 HESC were electroporated with a CAG-SOX17ER^-IRES-PURO plasmid. This plasmid contains a CAG promoter, the ORF for SOX 17
fused in frame to the estrogen receptor ligand binding domain (ER ), an independent
ribosomal entry site (IRES), and a puromycin resistance gene.

This transgene is
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constitutively expressed, but the SOX 17 transcription factor is only active following the
addition of 4-OH Tamoxifen.
To generate HESC lines for pancreatic differentiation, NGN3, PAX4 or PDX1
were introduced into both CA2 and CA2 CAG-SOX17-IRES-PURO HESC. To allow for
stable integration of the CAG-NGN3-IRES-NEO or CAG-PAX4-IRES-NEO transgenes,
these plasmids were linearized prior to electroporation.

Plasmids were linearized by

restriction enzyme digestion using Seal, which cuts once within the ampicillin resistance
gene. Following digestion, the linearized plasmid was purified by ethanol precipitation,
and resuspended in nuclease-free water to a concentration of 1pg/pL.
HESC with constitutive expression of NGN3 or PAX4 were generated by
electroporating CA2 or CA2 CAG-SOX17-IRES-PURO HESC with 20 pg of linearized
plasmid.

To generate HESC with constitutive expression of PDX1, cells were

electroporated with 4 pg of each of PB-TET-PDX1, PB-Transposase, and CAG-rtTAblasticidin. For electroporation, three wells of a 6 well dish of HESC were enzymatically
dissociated into single cells (0.05% Trypsin-EDTA) and centrifuged at 244 ref/g for three
minutes. The resultant cell pellet was resuspended in 400pL electroporation buffer and
added to a 4mm electroporation cuvette containing the desired plasmid.

The

electroporation cuvette was inserted into an electroporator (BioRad) and pulsed at 170V,
1050pF.

Cells were then plated into a 6 well dish and after 48 hours, transgene

expression was selected for using 0.8 pg/mL neomycin.
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To induce the expression of PDX1, 500ng/mL doxycycline was added to media
daily, 24 hours after electroporation. Following 48 hours of growth, cells were treated
with neomycin (lpg/m L) to select for expression of the PB-TET-PDX1 transgene.
To generate PB-TET-GFP HESC, 3pg of PB-TET-GFP, 5pg PB Transposase, and
5pg of CAG-rtTA-blasticidin plasmids were co-electroporated as described above into
CA1 HESC. Cells were plated onto on Matrigel coated dishes (Invitrogen) in media that
had been previously conditioned for 48 hours by mitotically inactivated mouse embryo
fibroblast feeders (MEF-conditioned media). Matrigel was required because MEFs are
not blasticidin resistant. After 48 hours, 5pg/mL blasticidin was added to culture media
to select for expression of the CAG-rtTA-blasticidin plasmid. Clonal, blasticidin resistant
colonies were picked each into one well of a four well dish on Matrigel in MEF
conditioned media. Upon confluency, cells were enzymatically passaged 1:4 into four
wells of a 12 well dish on Matrigel in MEF conditioned media.

Once cultures were

confluent, three wells were cryopreserved (90% FBS, 10% DMSO), and one well was
expanded for experimental purposes.

In total, 12 CA1 PB-TET-GFP clones were

generated.
To generate CA1 CAG-SOXH-ER^-PURO PB-TET-PDX1 HESC, 3pg of PBTET-PDX1, 3pg of PB Transposase, and 3pg of CAG-rtTA-blasticidin plasmids were
introduced into SOX17-ER12 HESC by electroporation, as described above.

After 48

hours, 5pg/mL blasticidin was added to culture media to select for integration of the
CAG-rtTA-blasticidin plasmid.

Clonal blasticidin resistant colonies were picked each

into one well of a four well dish on Matrigel in MEF conditioned media.

Upon

confluency, cells were enzymatically passaged 1:4 into four wells of a 12 well dish on
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Geltrex in MEF conditioned media.

Once cells were confluent, three wells were

cryopreserved (90% FBS, 10% DMSO), and one well was expanded for experimental
purposes. In total, 30 clonal populations of CA1 CAG-SOX17-ERT2-PURO PB-TETPDX1 HESC were generated.

2.4 Gene Expression Analysis
CA1 CAG-SOX17-ERT2-IRES-PURO HESC were plated into 12 well plates and
treated with 0.1 p.M 4-OH Tamoxifen in the absence of FGF2 for either two hours, 24
hours, two days, four days, or left untreated. At each timepoint, two wells of a 12 well
dish were rinsed with PBS and 0.5mL Trizol Reagent © was added to each well. Cells
were scraped and both wells were combined as one sample.
Following electroporation of CAG-NGN3-IRES-NEO, CAG-PAX4-IRES-NEO,
or PB-TET-PDX1 into CA2 or CA2 pClip CAG-SOX17-IRES-PURO HESC, cells were
maintained in HESC media with 1.0pg/mL G418.

The day of electroporation was

considered day 0. These cells were harvested at four days, eight days, 12 days, and 16
days following electroporation. At each timepoint, two wells of a 6 well dish were rinsed
with PBS and scraped in 0.5mL PBS.

Both wells were pooled as one sample and

centrifuged at 244 rcf/g for 3 minutes. The resultant cell pellet was resuspended in lmL
Trizol Reagent ©.
Total RNA was isolated using Trizol Reagent © (Invitrogen) according to the
manufacturer’s instructions and quantified by spectrophotometry on a Nanodrop 2000.
To generate cDNA, lpg of RNA was reverse transcribed using the iScript cDNA
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synthesis kit (BioRad) according to the manufacturer’s instructions using reverse
transcriptase and oligo(dT) and random primers. Gene expression was assessed by real
time PCR using the BioRad CFX384. PCR reactions were run in triplicate using 40ng of
cDNA per reaction and 400pM forward and reverse primers with 2X Sso Fast Eva Green
reaction mix (BioRad) and 40 cycles of amplification (95°C 2 min; 95°C lOsec; 60°C
30sec). Real-time PCR primers were designed to span intron-exon junctions, so that the
PCR product from genomic DNA can be distinguished from the PCR product from cDNA
through melt curve analysis.

Primer sets were run on a standard curve to ensure an

efficiency value between 90-110%. For every PCR experiment, specificity of primers
was determined by performing a melt curve from 65°C to 95°C after each run. Gene
expression was determined by relative quantification with values corrected for input using
TATA-binding protein (TBP) and normalized relative to undifferentiated CA1 HESC.
Analyses were performed in triplicate on three or four independent trials.

2.5 Immunostaining
Cells were fixed in 4% (w/vol) paraformaldehyde for 15 min at room temperature,
rinsed twice in PBS, and stored at 4°C in PBS until use. For immunocytochemistry, cells
were blocked for lhr in PBST (PBS, 0.1% Triton X - 100) with 5% fetal bovine serum
(FBS). Antibodies for SOX17 (R&D AF1924) 1:100, OCT3/4 (sc-5279) 1:400, NANOG
(ab80892) 1:400, and SSEA3 (mc-631) 1:10 were diluted in PBST with 5% FBS and
primary antibodies were incubated for one hour.

Cells were washed 2x10 min with

PBST, followed by incubation with species specific secondary antibodies Alexa Fluor
488 anti-goat IgG, anti-mouse IgG and anti-rabbit IgG 1:400 (Molecular Probes), and

43
Cy™5 anti-rat IgG 1:400 (Jackson ImmunoResearch) that were incubated for one hour at
room temperature diluted in PBST with 5% FBS. Cells were washed 2x10 min with
PBST, followed by nuclear staining using lpg/mL Hoechst 33258 in PBST for 10 min.
Cells were washed 2x10 min with PBS, and stored in PBS for imaging. Fluorescence
images were taken with a Zeiss Imager using a 10X objective, as well as a Leica DM6000
inverted fluorescent microscope.

Fluorescence imaging was performed on three

independent trials.
2.6 LacZ Staining
To observe the functionality of CA1 SOX17-ER t2/PB-TET-PDX1 HESC through
the expression of (3-galactosidase, which is downstream of PDX1, cells were treated with
500ng/mL doxycycline for 4 days to induce the PB-TET-PDX1 transgene. Cells were
then fixed in 0.25% glutaraldehyde for 15 min at room temperature, rinsed twice in PBS
and covered in X-gal solution (0.2% X-gal, 2mM MgCl2 , 5mM K4Fe(CN)6*3H20, 5mM
K 3 Fe(CN >6 in PBS) and incubated overnight at room temperature. X-gal solution was
removed, cells were rinsed twice with PBS, covered with PBS and incubated until blue
staining was visible. Staining was imaged on a Nikon SMZ-1500 stereoscope.

2.7 Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 4.00. Real-time
PCR quantification was examined using a one-way ANOVA and Dunnett’s post-test, as
well as using a two-way ANOVA and Bonferroni post-test.
significant.

p<0.05 was considered

3.0 RESULTS
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3.1 Constitutive expression of PAX4 in CA2 HESC does not change cell morphology.
To assess the ability of ectopic expression of PAX4 to specify pancreatic
endocrine cells from pluripotent HESC, a transgene confering constitutive expression of
pCAGS-PAX4-IRES NEO was introduced into CA2 HESC.

Transgenic HESC were

maintained as previously described and cells were imaged and RNA was isolated at 4, 8,
12 and 16 day timepoints following electroporation. The day of electroporation was
considered day 0.

There was no observable change in cell morphology following

constitutive expression of PAX4 in CA2 HESC during this time period (Figure 3.1 A).
Real time PCR analysis of PAX4 gene expression was performed (Figure 3.1 B).
Expression of the PAX4 transgene showed a trend towards decreased expression over
time in the resultant transgenic cell populations.

3.2 Constitutive expression of PAX4 in DE cells does not change cell morphology.
To assess the ability of ectopic expression of PAX4 to specify pancreatic
endocrine cells from definitive endoderm, pCAGS-PAX4-ERES NEO was introduced into
SOX17 expressing HESC (DE). There was no change in morphology of DE cells in the
presence of constitutive PAX4 expression (Figure 3.2 A). Real time PCR analysis of
SOX17 and PAX4 gene expression was performed (Figure 3.2 B). Expression of both
SOX 17 and PAX4 transgenes showed a trend towards decreased expression over time in
the resultant transgenic cell populations. This finding is in keeping with the initial
characterization of the SOX17 HESC lines (Seguin et al., 2008), which demonstrated
decreased SOX17 expression with cell differentiation.

Figure 3.1 Constitutive expression of PAX4 in CA2 HESC does not change cell
morphology.
(A) Photomicrographs of replicate populations of CA2 PAX4 HESC imaged at 4, 8, 12
and 16 day timepoints following electroporation. The day of electroporation was
considered day 0. A transgene conferring constitutive expression of pCAGS-PAX4-IRES
NEO was introduced into CA2 HESC (scale bars, 500 pm). There was no observable
change in morphology following PAX4 expression in CA2 HESC. (B) Real time PCR
quantification of PAX4 expresssion in resultant cell populations at 4, 8, 12 and 16 day
time points. Values were corrected for input using the expression of TBP and expressed
relative to undifferentiated HESC, (n=2). For PAX4, the SEM of technical replicates was
not greater than 3.456.
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Figure 3.2 Constitutive expression of PAX4 in DE cells does not change cell
morphology.
(A) Photomicrographs of replicate populations of SOX 17 PDX1 HESC imaged at 4, 8, 12
and 16 day timepoints following electroporation. The day of electroporation was
considered day 0. A transgene conferring constitutive expression of pCAGS-PAX4-IRES
NEO was introduced into SOX17 expressing HESC (DE) (scale bars, 500 pm). There
was no observable change in morphology following expression of PAX4 in DE cells. (B)
Real time PCR quantification of PAX4 and SOX17 expression in resultant cell
populations at 4, 8, 12 and 16 day time points. Values were corrected for input using the
expression of TBP and expressed relative to undifferentiated HESC.

Real time PCR

analysis of SOX 17 and PAX4 gene expression showed a decreasing trend in both
transgenic cell populations, (n=2). For PAX4, the SEM of technical replicates was not
greater than 2.459. For SOX17, the SEM of technical replicates was not greater than
0.8294.
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3.3 Constitutive expression of PAX4 in CA2 HESC and DE cells does not change cell
phenotype.
To assess the gene expression profiles of cells following constitutive expression of
PAX4, real time PCR was performed.

To assess changes to cell phenotype following

transgene expression, cells were directly compared to HESC subjected to growth factor
mediated differentiation using previously established protocols (D'Amour et al., 2006).
We first assessed the expression of markers of DE including Cerberus 1 (CER1), C-X-C
chemokine receptor type 4 (CXCR4), and distal-less homeobox 5 (DLX5) (Figure 3.3 AC). In both CA2 HESC and DE cells, PAX4 overexpression resulted in a trend towards
decreased CER1 and CXCR4 gene expression over 16 days of differentiation. However,
DLX5 gene expression was increased at day 16 in SOX17 PAX4 HESC.

We next

examined the expression of markers of early pancreatic differentiation including PDX1
and paired box gene 6 (PAX6). PDX1 and PAX6 showed decreased expression in both
transgenic cell populations after 16 days of differentiation compared to unmodified CA1
HESC (Figure 3.3 D-E).

Next, markers of pancreatic progenitors NK2 homeobox 2

(NKX2.2) and NK6 homeobox 1 (NKX6.1) were examined. There was no difference in
NKX2.2 and NKX6.1 gene expression compared to unmodified CA1 HESC and growthfactor mediated pancreatic differentiation (Figure 3.3 G-H).

To assess pancreatic

hormone gene expression, we quantified mRNA levels of insulin (INS), glucagon (GCG)
and somatostatin (SST) mRNA. Expression of INS showed a trend towards increased
expression in both transgenic cell populations at day 12 and 16 compared to growth factor
mediated pancreatic differentiation (Figure 3.3 I). Conversely, GCG and SST expression
did not differ compared to unmodified CA1 HESC, levels below those detected in growth
factor mediated pancreatic differentiation (Figure 3.3 J-K). Lastly, cytokeratin 19

Figure 3.3 Constitutive expression of PAX4 in CA2 HESC and DE cells does not
change cell phenotype
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8,
12 and 16 day time points following electroporation. The day of electroporation was
considered day 0.

Values were corrected for input using the expression o f TBP and

expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM
from duplicate experiments (n=2).

(A-C) To assess DE differentiation, expression of

CER1, CXCR4 and DLX5 was quantified.

(D-F) To assess early pancreatic

differentiation, expression of PAX6, PDX1 and NGN3 was quantified. (G-H) To assess
pancreatic progenitor differentiation, expression of NKX2.2 and NKX6.1 was quantified.
(I-K) Expression of pancreatic hormones INS, GCG and SST were quantified. (L-M) To
assess exocrine differentiation, expression of CK19 and AMY was quantified.
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(CK19), and amylase (AMY) were investigated as markers of pancreatic ductal
epithelium and exocrine differentiation respectively (Figure 3.3 L-M). Both transgenic
cell populations had no change in CK19 expression compared to unmodified CA1 HESC
until day 16 when SOX17 PAX4 HESC showed increased gene expression compared to
CA2 PAX4 HESC and unmodified CA1 HESC (Figure 3.3 L-M).

Throughout the

timecourse, CK19 expression in these transgenic cell populations remained lower than in
growth factor mediated pancreatic differentiation. AMY expression remained unchanged
throughout the timecourse for both transgenic cell populations compared to unmodified
CA1 HESC, while AMY gene expression was detected following growth factor mediated
pancreatic differentiation.

Taken together, these data suggest that overexpression of

PAX4 does not promote pancreatic endocrine differentiation from HESC or DE.

3.4 Constitutive expression of PAX4 in CA2 HESC and DE cells does not result in
mesodermal or ectodermal differentiation by day 16.
To determine if constitutive expression of PAX4 in HESC or DE cells resulted in
differentiation to mesodermal or ectodermal lineages, selected marker genes were
examined by real time PCR. To assess mesodermal differentiation, TEK tyrosine kinase
(TIE2) and NK2 homeobox 5 (NKX2.5) were investigated (Figure 3.4 A-B). TIE2 gene
expression was unchanged in both transgenic cell populations when compared to
unmodified CA1 HESC.

NKX2.5 gene expression decreased in both transgenic cell

populations when compared to unmodified CA1 HESC.

Next, SOX3 and NESTIN,

markers of ectodermal differentiation were examined (Figure 3.4 C-D). There was no

Figure 3.4 Constitutive expression of PAX4 in CA2 HESC and DE cells does not
result in mesodermal or ectodermal differentiation by day 16.
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8,
12 and 16 day time points following electroporation. The day of electroporation was
considered day 0. Values were corrected for input using the expression o f TBP and
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM
from duplicate experiments (n=2). (A-B) Expression o f mesodermal markers TIE2 and
NKX2.5 were quantified. (C-D) Expression of ectodermal markers SOX3 and NESTIN
were quantified.
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robust induction of either SOX3 or NESTIN gene expression observed when compared to
unmodified CA1 HESC.

3.5 Constitutive expression of PDX1 in CA2 HESC results in cells with a flattened
morphology after 16 days.
To assess the ability of PDX1 to specify pancreatic endocrine cells from
pluripotent HESC, PB-TET-PDX1 was introduced into CA2 HESC. Transgenic HESC
were maintained under standard conditions in media supplemented with 500ng/mL
doxycycline to induce ectopic expression of PDX1. Cells were imaged and RNA was
isolated at 4, 8, 12 and 16 day timepoints following electroporation (Figure 3.5 A). The
day of electroporation was considered day 0. In transgenic populations A and B, cells
adopted a more flattened morphology beginning at day 12, while transgenic population C
adopted this morphology by day 16 (Figure 3.5 B). Real-time PCR analysis of PDX1
gene expression was performed in the 3 seperate replicate populations (Figure 3.5 C).
Although all 3 populations had significantly increased PDX1 expression at day 4
compared to unmodified HESC, transgenic population C was shown to have the lowest
amount of PDX1 transgene expression, demonstrating a 1402 fold increase vs HESC
controls when compared to populations A and B which demonstrated relative expression
values of 27071 fold and 24106 fold increase vs HESC controls respectively. However,
PDX1 gene expression demonstrated a dramatic decrease over time in all three cell
populations.

Figure 3.5 Constitutive expression of PDX1 in CA2 HESC results in cells with a
flattened morpology after 16 days.
(A) Photomicrographs of replicate populations of CA2 PDX1 HESC imaged at 4, 8, 12
and 16 day timepoints following electroporation. The day of electroporation was
considered day 0.

A transgene conferring constitutive expression of PDX1 was

introduced into CA2 HESC (scale bars, 500 pm).

Following 16 days of constitutive

PDX1 expression, cells adopted a flattened morphology. (B) Photomicrographs of CA2
PDX1 HESC at 4 days and 16 days demonstrating the flattened morphology o f these cells
at 16 days (scale bars, 500 pm). (C) Real time PCR quantification of PDX1 expresssion
in resultant cell populations at 4, 8, 12 and 16 day time points. Values were corrected for
input using the expression of TBP and expressed relative to undifferentiated HESC,
(n=3). For PDX1, the SEM of technical replicates was not greater than 1.982.

58
A

CA2PDXl

4 DAY

4 DAY

8 DAY

12 DAY

16 DAY

16 DAY

59
3.6 Constitutive expression of PDX1 in DE cells does not change cell morphology.
To assess the ability of PDX1 to specify pancreatic endocrine cells from definitive
endoderm, PB-TET-PDX1 was introduced into SOX17 expressing HESC (DE).
Transgenic SOX17 HESC were maintained in media supplemented with 500ng/mL
doxycycline to induce ectopic expression of PDX1.

There was no change in cell

morphology of DE cells in the presence of ectopic PDX1 expression (Figure 3.6 A). Real
time PCR analysis of SOX17 and PDX1 gene expression was also performed (Figure 3.6
B). SOX17 gene expression showed a decreasing trend in all transgenic cell populations.
PDX1 gene expression varied substantially between the 3 replicate experiments and
showed a trend of decreased expression over time in transgenic populations A and C.

3.7 Constitutive expression of PDX1 in DE cells results in insulin gene expression by
day 16.
To assess gene expression profiles of cells engineered to constitutively express
PDX1, we performed real time PCR.

CER1, CXCR4, and DLX5 were once again

examined as markers of DE (Figure 3.7A-C). There was no difference between CA2
PDX1 HESC and SOX 17 PDX1 HESC at any of the timepoints examined. Markers of
early pancreatic development including PAX4, PAX6 and NGN3 were also examined
(Figure 3.7D-F). There were no differences in early pancreas gene expression in either
transgenic cell population compared to unmodified CA1 HESC.

Next, NKX2.2 and

NKX6.1, markers of pancreatic progenitor differentiation, were assessed (Figure 3.7G-H).
Following four days of ectopic PDX1 expression, both NKX2.2 and NKX6.1 expression
showed a trend towards increased expression in SOX17 PDX1 HESC compared to CA2

Figure 3.6 Constitutive expression of PDX1 in DE cells does not change cell
morphology.
(A) Photomicrographs of replicate populations of SOX 17 PDX1 HESC imaged at 4, 8, 12
and 16 day timepoints following electroporation. The day of electroporation was
considered day 0.

A transgene conferring constitutive expression of PDX1 was

introduced into DE cells (scale bars, 500 pm). (B) Real time PCR quantification of PDX1
and SOX17 expresssion in resultant cell populations at 4, 8, 12 and 16 day time points.
Values were corrected for input using the expression TBP and expressed relative to
undifferentiated HESC (n=3).

SOX 17 showed a trend towards decreasing gene

expression in all transgenic cell populations.

PDX1 gene expression was variable

between the 3 replicate experiments. For PDX1, the SEM was not greater than 1.592.
For SOX17, the SEM was not greater than 0.912.
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Figure 3.7 Constitutive expression of PDX1 in DE cells results in insulin gene
expression by day 16.
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8,
12 and 16 day time points following electroporation. The day of electroporation was
considered day 0. Values were corrected for input using the expression o f TBP and
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM
from triplicate experiments (n=3).

(A-C) To assess DE differentiation, expression of

CER1, CXCR4 and DLX5 was quantified.

(D-F) To assess early pancreatic

differentiation, expression of PAX4, PAX6 and NGN3 was quantified. (G-H) To assess
pancreatic progenitor differentiation, expression of NKX2.2 and NKX6.1 was quantified.
(I-K) Expression of pancreatic hormones INS, GCG and SST were quantified. (L-M) To
assess exocrine differentiation, expression of CK19 and AMY was quantified, (n=3).
Statistical analysis was performed in two ways with p<0.05 considered significant.

1)

One way ANOVA with a Dunnett’s post hoc test to compare all time points to
undifferentiated HESC. (* indicates significance from unmodified HESC) 2) Two-way
ANOVA with a Bonferroni post hoc test to compare treatments within time points, (a
indicats significance from CA2 PDX1 HESC, b indicates significance from growth factor
mediated pancreatic differentiation, c indicates significance from SOX 17 PDX1 HESC).
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PDX1 HESC and growth-factor mediated pancreatic differentiation. We then quantified
expression of the pancreatic hormones INS, GCG and SST (Figure 3.7I-K). By day 16,
INS gene expression in SOX17 PDX1 HESC was significantly increased compared to
both CA2 PDX1 and growth factor mediated pancreatic differentiation, while GCG and
SST gene expression did not differ between SOX17 PDX1 and CA2 PDX1 HESC.
Lastly, CK19 and AMY, markers of ductal epithelium and exocrine pancreas were
examined. There were no changes in exocrine gene expression in SOX 17 PDX1 and
CA2 PDX1 HESC compared to unmodified CA1 HESC, however gene expression was
lower than growth factor mediated pancreatic differentiation. Taken together, this data
demonstrates that ectopic PDX1 expression in DE cells results in significantly increased
insulin gene expression following 16 days of differentiation, however this is not
accompanied by significant induction of any other markers of pancreatic endocrine
differentiation examined.

3.8 Constitutive expression of PDX1 in CA2 HESC or DE cells does not result in
mesodermal or ectodermal differentiation by day 16.
To determine if constitutive expression of PDX1 in HESC or DE cells resulted in
differentiation to mesodermal or ectodermal lineages, selected marker genes were
examined by real time PCR. To assess mesodermal differentiation, TIE2 and NKX2.5
expression were investigated (Figure 3.8A-B). TIE2 gene expression was significantly
increased in both transgenic cell populations at the 4 day timepoint when compared to

Figure 3.8 Constitutive expression of PDX1 in CA2 HESC or DE cells does not result
in mesodermal or ectodermal differentiation by day 16.
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8,
12 and 16 day time points following electroporation. The day of electroporation was
considered day 0. Values were corrected for input using the expression of TBP and
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM
from duplicate experiments (n=3). (A-B) Expression of mesodermal markers TIE2 and
NKX2.5 were quantified. (C-D) Expression of ectodermal markers SOX3 and NESTIN
were quantified, (n=3). Statistical analysis was performed in two ways with p<0.05
considered significant. 1) One way ANOVA with a Dunnett’s post hoc test to compare
all time points to undifferentiated HESC. (* indicates significance from unmodified
HESC) 2) Two-way ANOVA with a Bonferroni post hoc test to compare treatments
within time points (a indicats significance from CA2 PDX1 HESC, b indicates
significance from growth factor mediated pancreatic differentiation, c indicates
significance from SOX17 PDX1 HESC).

Ectoderm

M e s o d e rm

66

A
T IE 2
ß
N KX2.5

67
unmodified CA1 HESC.

NKX2.5 gene expression was not significantly altered from

undifferentiated HESC.

Next, NESTIN, a marker of ectodermal differentiation was

examined (Figure 3.8C). NESTIN gene expression was significantly increased at 4 day
timepoints in both transgenic populations compared to unmodified CA1 HESC. Taken
together, these results suggest that at early timepoints, there is mixed differentiation with
ectopic PDX1 expression in CA2 and DE cells, producing early stages of mesendodermal
and neurectodermal differentiation, however by day 16, there is no observable change in
mesodermal and ectodermal markers compared to unmodified CA1 HESC.

3.9 Constitutive expression of NGN3 in HESC does not alter cell morphology.
To assess the ability of ectopic expression of NGN3 to specify pancreatic
endocrine cells from pluripotent HESC, a transgene conferring constitutive expression of
pCAGS-NGN3-ERES NEO was introduced into CA2 HESC. Transgenic HESC were
maintained under standard conditions in media supplemented with G418 to select for
transgene expression for up to 16 days and cells were imaged and RNA was isolated at 4,
8, 12 and 16 day timepoints following electroporation. The day of electroporation was
considered day 0. There was no change in cell morphology in CA2 HESC in the presence
of constitutive NGN3 expression (Figure 3.9 A). Real-time PCR analysis of NGN3 gene
expression was performed in the 4 separate replicate populations (Figure 3.9 B).
Transgenic population A and C had relative expression values of 436526 and 75701- fold
increase vs unmodified HESC controls respectively at day 4, compared to population B
and D which had lower NGN3 transgene expression at 1061 and 340- fold increase vs
unmodified HESC controls.

Figure 3.9 Constitutive expression of NGN3 in HESC does not alter cell morphology
(A) Photomicrographs of replicate populations of CA2 NGN3 HESC imaged imaged at 4,
8, 12 and 16 day timepoints following electroporation. The day of electroporation was
considered day 0.

A transgene conferring constitutive expression of pCAGS-NGN3-

IRES NEO was introduced into CA2 HESC (scale bars, 500 pm).

There was no

observable change in morphology following NGN3 expression in CA2 HESC. (B) Real
time PCR quantification of NGN3 expresssion in resultant cell populations at 4, 8, 12 and
16 day time points. Values were corrected for input using the expression o f TBP and
expressed relative to undifferentiated HESC, (n=4). For NGN3, the SEM was not greater
than 3.402.
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3.10 Constitutive expression of NGN3 in DE ceils results in a flattened morphology
and the presence of cytoplasmic vacuoles.
To assess the ability of NGN3 to specify pancreatic endocrine cells from cells
already committed to the definitive endoderm lineage, the constitutive pCAGS-NGN3IRES-NEO transgene was introduced into HESC constitutively expressing SOX17 (DE
cells). As described above, transgenic HESC were maintained for up to 16 days and cells
were imaged at 4, 8, 12 and 16 day timepoints following electroporation (Figure 3.10 A).
The day of electroporation was considered day 0. Following 4 days of NGN3 expression,
there was no detectable change in cell morphology when compared to DE cells. At day
eight, cells began to appear more flattened and small vacuoles were observed within the
cytoplasm. Throughout the rest of the timecourse, cells maintained this altered flattened
morphology and spread out, with some cells maintaining the presence of vacuoles at day
16 (Figure 3.10 B). Real-time PCR analysis of SOX17 and NGN3 was performed in the 4
separate replicate populations (Figure 3.10 C).

Population A had the highest NGN3

transgene expression with a relative expression value of 11565 fold compared to
unmodified HESC controls. Population B had 892-fold NGN3 expression, while
population C had 1482-fold expression and population D had 219 fold NGN3 expression
compared to unmodified HESC controls.

Additionally, each transgenic population

showed a decreasing trend of SOX17 expression over 16 days.

Figure 3.10 Constitutive expression of NGN3 in DE cells results in a flattened
morphology and the presence of cytoplasmic vacuoles.
(A) Photomicrographs of replicate populations of CA2 NGN3 HESC imaged at 4, 8, 12
and 16 day timepoints following electroporation. The day of electroporation was
considered day 0.

A transgene conferring constitutive expression of NGN3 was

introduced into CA2 HESC (scale bars, 500 pm). Following 8 days of NGN3 expression,
cells adopted a flattened morphology with the presence of cytoplasmid vacuoles, with this
morphology being maintained over the duration of the timecourse. (B) Photomicrographs
of SOX 17 NGN3 HESC at 4 days and 16 days demonstrating the flattened morphology
and cytoplasmic vacuoles within these cells at day 16 (scale bars, 500 pm). (C) Real time
PCR quantification of NGN3 and SOX17 expresssion in resultant cell populations at 4, 8,
12 and 16 day time points. Values were corrected for input using the expression of TBP
and expressed relative to undifferentiated HESC, (n=4). SOX 17 showed a trend towards
decreased gene expression in all transgenic populations. NGN3 demonstrated variable
gene expression between replicate populations. For NGN3, the SEM was not greater than
2.019. For SOX17, the SEM was not greater than 1.023.
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3.11 Constitutive expression of SOX17 and NGN3 in HESC drives cells to a
pancreatic endocrine fate.
To assess the gene expression profiles of cells that constitutively expressed
NGN3, we performed real time PCR. To assess the efficiency of differentiation, cells
were directly compared to HESC subjected to growth factor mediated differentiation
using previously established protocols (D'Amour et al., 2006).

We first assessed the

expression of markers of DE including CER1, CXCR4, and DLX5 (Figure 3.11 A-C). In
both CA2 HESC and DE cells, NGN3 overexpression results in a trend towards decreased
DE gene expression by 16 days of differentiation. We next examined the expression of
markers of early pancreatic differentiation including PAX4, PAX6 and PDX1. By day
12, PAX4 expression is increased in cells that contain both SOX 17 and NGN3
transgenes, in comparison to CA2 NGN3 HESC and growth-factor mediated pancreatic
differentiation (Figure 3.11 D). Additionally, PAX6 expression was increased in both
transgenic cell lines by day 16 compared to growth-factor mediated pancreatic
differentiation (Figure 3.11 E). At day 8 and 12, PDX1 gene expression shows a trend
towards increased gene expression in SOX17 NGN3 HESC compared to both CA2
NGN3 HESC in addition to growth-factor mediated pancreatic differentiation (Figure
3.11 F). Next, markers of pancreatic progenitors NK2 homeobox 2 (NKX2.2) and NK6
homeobox 1 (NKX6.1) were examined. At eight days of differentiation, NKX2.2 gene
expression was increased in SOX 17 NGN3 HESC in comparison to both CA2 NGN3
HESC

and growth-factor mediated

pancreatic differentiation

(Figure 3.11

G).

Additionally, NKX6.1 gene expression was significantly increased in SOX17 NGN3
HESC at day 12 in comparison to CA2 NGN3 HESC, growth-factor mediated pancreatic
differentiation, and unmodified HESC controls (Figure 3.11 H).

Figure 3.11 Constitutive expression of SOX17 and NGN3 in HESC drives cells to a
pancreatic endocrine fate.
Real time PCR quantification of gene expression in transgenic NGN3 populations at 4, 8,
12 and 16 day time points following electroporation. The day of electroporation was
considered day 0. Values were corrected for input using the expression o f TBP and
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM
from quadruplicate experiments (n=4). (A-C) To assess DE differentiation, expression of
CER1, CXCR4 and DLX5 was quantified.

(D-F) To assess early pancreatic

differentiation, expression of PAX4, PAX6 and PDX1 was quantified. (G-H) To assess
pancreatic progenitor differentiation, expression of NKX2.2 and NKX6.1 was quantified.
(I-K) Expression of pancreatic hormones INS, GCG and SST were quantified. (L-M) To
assess exocrine differentiation, expression of CK19 and AMY was quantified. Statistical
analysis was performed in two ways with p<0.05 considered significant.

1) One way

ANOVA with a Dunnett’s post hoc test to compare all time points to undifferentiated
HESC (* indicates significance from unmodified HESC). 2) Two-way ANOVA with a
Bonferroni post hoc test to compare treatments within time points, (a indicats significance
from CA2 NGN3 HESC, b indicates significance from growth factor mediated pancreatic
differentiation, c indicates significance from SOX17 NGN3 HESC).
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To assess pancreatic hormone gene expression, we quantified mRNA levels of
INS, GCG and SST. Expression of INS was significantly increased in CA2 NGN3 HESC
at day 12 compared to unmodified HESC controls, while SOX 17 NGN3 HESC showed a
trend towards increased INS gene expression throughout the timecouse (Figure 3.11 I).
Conversely, GCG and SST expression did not differ compared to growth factor mediated
pancreatic differentiation in both cell types until day 16, when CA2 NGN3 HESC had
significantly increased SST compared to unmodified HESC controls (Figure 3.11 J-K).
Lastly, cytokeratin 19 (CK19), and amylase (AMY) were investigated as markers of
pancreatic ductal epithelium and exocrine differentiation respectively (Figure 3.11 L-M).
In both transgenic cell populations, there was no change in ductal or exocrine gene
expression, however they had lower gene expression compared to growth factor mediated
pancreatic differentiation. Taken together, overexpression of NGN3 in DE cells suggests
differentiation towards pancreatic endocrine progenitors.

3.12 Constitutive expression of NGN3 in CA2 HESC and DE cells does not result in
mesodermal or ectodermal differentiation.
To examine the specificity of NGN3-induced differentiation in CA2 HESC and
DE cells, we examined the expression of markers of both the mesodermal and ectodermal
lineages.

To assess mesodermal differentiation, TIE2 and NKX2.5 were investigated

(Figure 3.12 A-B). At day 4, TIE2 was significantly upregulated in CA2 NGN3 HESC,
however by day 16, there was no robust induction of mesodermal gene expression
compared to unmodified CA1 HESC.

Secondly, to investigate ectodermal gene

expression, we determined the levels of SOX3 and NESTIN (Figure 3.12 C-D). No

Figure 3.12 Constitutive expression of NGN3 in CA2 HESC and DE cells does not
result in mesodermal or ectodermal differentiation.
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8,
12 and 16 day time points following electroporation. The day of electroporation was
considered day 0.

Values were corrected for input using the expression o f TBP and

expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM
from quadruplicate experiments (n=4). (A-B) Expression of mesodermal markers TIE2
and NKX2.5 were quantified.

(C-D) Expression o f ectodermal markers SOX3 and

NESTIN were quantified. Statistical analysis was performed in two ways with p<0.05
considered significant. 1) One way ANOVA with a Dunnett’s post hoc test to compare
all time points to undifferentiated HESC (* indicates significance from unmodified
HESC). 2) Two-way ANOVA with a Bonferroni post hoc test to compare treatments
within time points. (a indicats significance from CA2 NGN3 HESC, b indicates
significance from growth factor mediated pancreatic differentiation, c indicates
significance from SOX17 NGN3 HESC).
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significant induction of either NESTIN or SOX3 gene expression was induced by ectopic
NGN3 expression in either transgenic cell population relative to unmodified CA1 HESC.
Taken together, these findings suggest that constitutive expression of NGN3 in CA2
HESC and DE cells does not promote mesodermal or ectodermal differentiation.

3.13 Characterization of DE differentiation using inducible SOX17 activation in
HESC

3.13.1 4-OH Tamoxifen regulates SOX17 transgene cytoplasmic location.
During

development,

SOX 17

is

expressed

during

DE

formation,

and

downregulated following formation of the gut tube (Kanai-Azuma et al., 2002). In order
to better recapitulate this developmental pattern of transient expression, clonal HESC cell
lines expressing a transgene conferring inducible activation of the SOX 17 transcription
factor were previously generated in the Séguin lab. The SOX17 coding sequence was
fused in frame to the estrogen receptor ligand binding domain (ER ) to generate a
protein that is constitutively expressed but active only following the addition of 0.1 pM 4OH Tamoxifen to culture media (Hayashi and McMahon, 2002). This inducible construct
permits control of the duration of transcription factor activity, which is imperative when
developing a differentiation strategy aimed at mimicking the developmental pattern of
transcription factor activity. To visualize SOX 17 localization, immunocytochemistry was
performed on SOX17-ER17 HESC that were either untreated (maintained under standard
culture conditions), or treated with 0.1 pM 4-OH Tamoxifen for 2 hours, 24 hours, 2 days

Figure 3.13.1 4-OH Tamoxifen regulates SOX17 transgene cytoplasmic location.
Immunocytochemistry demonstrating cellular localization o f SOX17.

SOX17-ERT2-

PURO HESC were treated with 0.1 pM 4-OH Tamoxifen for 2 hours, 24 hours, 2 days, 4
days, or left untreated. Cells were analyzed by standard immunocytochemistry protocols
using a polyclonal antibody for SOX17. SOX17 is restricted to the cytoplasm until the
addition of 4-OH Tamoxifen, when it undergoes nuclear translocation within 2 hours,
(n=3), scale bars 200pM.

82

Length o f Tam oxifen Exposure

S0X 17/D A PI

SOX 17

0 HR

2 HR

24 H R

2 DAY

4 DAY

83
or four days (Figure 3.13.1). Immunolocalization of SOX17 demonstrated that SOX17ER

rV/m
%

was restricted to the cytoplasm prior to 4-OH Tamoxifen addition, however nuclear

translocation is detected within 2 hours of 4-OH Tamoxifen addition, a cellular
localization that is maintained in the continued presence of 4-OH Tamoxifen up to 4 days.

3.13.2 HESC adopt a DE phenotype following 4 days ofSO X17 activation.
To determine the duration of SOX 17 activation required to induce DE
differentiation, CA1 SOX17-ERT2 HESC were treated with 4-OH Tamoxifen for up to 4
days.

Gene expression was quantified by real-time PCR with values corrected for TBP

and normalized to unmodified CA1 HESC. Gene expression was compared to SOX 17ER

HESC cultured in media without bFGF to compare transcription factor mediated

differentiation to spontaneous differentiation. Genes investigated were, CER1, CXCR4,
DLX5 (definitive endoderm), GATA4, GATA6, HNF4a (pan-endoderm), and OCT4,
NANOG (pluripotency) using previously validated primer sets.

DE markers were

upregulated within 24 hours, and significantly expressed by 4 days of 4-OH Tamoxifen
exposure (Figure 3.13.2A).

The pan-endoderm markers GATA4 and GATA6 were

significantly increased following 4 days of 4-OH Tamoxifen treatment (Figure 3.13.2B).
The expression of pluripotency markers remain unchanged throughout the timecourse
(Figure 3.13.2C), findings in keeping with the previous characterization of the
constitutive SOX17 expressing HESC which maintain OCT4 and NANOG expression
despite their DE phenotype (Seguin et al., 2008). Taken together, these data suggest that
cells adopt a definitive endoderm phenotype following 4 days of SOX17 activation.

Figure 3.13.2 HESC adopt a DE phenotype following 4 days of SOX17
overexpression
(A) Schematic representation of the SOX17-ERT2-PURO transgene used for SOX 17
delivery.

(B-D) SYBR-based RT-PCR analysis of gene expression in SOX17-ER12

HESC treated with 4-OH Tamoxifen for 2 hours, 24 hours, 2 days or 4 days. Expression
of DE markers, pluripotency markers, and pan-endoderm markers suggests the robust
induction of DE differentiation within 4 days. Gene expression normalized to TBP and
expressed relative to untreated CA1 HESC (n=3). Furthermore, gene expression was
compared to SOX17-ER12 HESC cultured in media without bFGF to compare
transcription factor mediated differentiation to spontaneous differentiation. Statistical
analysis was performed using a one way ANOVA with a Dunnett’s post hoc test to
compare all time points to undifferentiated HESC. P<0.05 was considered significant (*
indicates significance from unmodified HESC).
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3.14 Characterization of an inducible system for second transgene delivery.

3.14.1 The piggyBac system is induced in HESC by doses o f doxycycline lOOng/mL or
greater.
CA1 HESC were co-electroporated with a PB-TET-GFP plasmid (generated by J
Rossant, SickKids), PB transposase plasmid, and PB-rtTA-blasticidin to generate novel
clonal transgenic cell lines with doxycycline inducible GFP expression. To determine the
dose of doxycycline required to induce transgene expression, two independent clonal cell
lines were treated with increasing doses of doxycycline and imaged for GFP fluorescence
up to 24hrs after doxycycline addition (Figure 3.14.1). The GFP transgene was induced
by concentrations of doxycycline between lOOng/mL and lOOOng/mL, with no
fluorescence detected at doses below lOOng/mL. Detection of fluorescence began 24
hours after the addition of doxycycline at concentrations of doxycycline at lOOng/mL or
greater.

3.14.2 The piggyBac system is maximally induced by 500ng/mL doxycycline.
To verify our fluorescence findings quantitatively, PB-TET-GFP cells were
exposed to the same concentrations of doxycycline for 24 hours prior to harvesting for
RNA extraction for real-time PCR. The expression of GFP was examined. In PB-TETGFP clone D, GFP was found to increase approximately 50 fold when treated with
lOOng/mL doxycycline and approximately 104 fold when treated with lOOOng/mL and
500ng/mL doxycycline (Figure 3.14.2A). In PB-TET-GFP clone E, GFP increased

Figure 3.14.1 The piggyBac system is induced by doses of doxycycline lOOng/mL or
greater
Fluorescence imaging of PB-TET-GFP HESC treated with increasing doses of
doxycycline and imaged over 24 hours. Novel transgenic CA1 HESC containing the PBTET-GFP transgene were subjected to increasing doses of doxycycline to visualize the
activity of the PB-TET system in HESC. Tet-induced GFP expression was detected at
concentrations of doxycycline lOOng/mL or greater, with detection beginning following
24hrs of doxycycline treatment (n=l), scale bars lOOpM.
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Figure 3.14.2 The piggyBac system is maximally induced by 500ng/mL doxycycline.
SYBR-based RT-PCR analysis of PB-TET-GFP cells. Two clonal populations of PBTET-GFP HESC were treated with increasing concentrations of doxycycline for 24 hours
to induce GFP expression. GFP is detected at doses lOOng/mL or greater, with maximal
GFP at a dose of 500ng/mL.
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approximately 50 fold when treated with lOOng/mL doxycycline and approximately 103
fold when treated with lOOOng/mL and 500ng/mL doxycycline (Figure 3.14.2B). For
both clones, there was little detectable GFP induction at doses below lOOng/mL

3.14.3 The piggyBac system turns o ff following the removal o f doxycycline.
To ensure that transgene expression was reversable, doxycycline was removed
from the culture media after 24 hours and cells were imaged for an additional 72 hours
(Figure 3.14.3). The levels of GFP remained consistent at all doses of doxycycline until
48 hours after removal when the levels of GFP showed a marked decrease.

3.14.4 The dose o f doxycycline used fo r piggyBac induction (500ng/mL) does not affect
HESC phenotype.
To ensure that the dose of doxycycline used to induce the PB system did not alter
the HESC phenotype, PB-TET-GFP HESC, cells were treated with 500ng/mL
doxycycline for 24 hours, and immunocytochemistry was performed to examine levels of
OCT 4, NANOG and SSEA3 as markers of pluripotency (Figure 3.14.4A). Following 24
hours of doxycycline treatment, there was no detectable change in the expression of these
markers when compared to untreated HESC. To verify these findings quantitatively, four
additional HESC lines were treated with 500ng/mL doxycycline for either 24 hours or
four days and the expression of OCT4, NANOG and SOX2 was quantified by real-time
PCR (Figure 3.14.4B). Following both 24 hour and four day doxycycline treatment, there

Figure 3.14.3 The piggyBac system turns off following the removal of doxycycline
Fluorescence imaging of PB-TET-GFP HESC exposed to increasing doses of doxycycline
and imaged up to 72 hours following doxycycline removal. After 48hrs, levels of GFP
decreased demonstrating that the system had been turned off, (n=l), scale bars lOOpM.
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Figure 3.14.4 The dose of doxycycline used for piggyBac induction (500ng/mL) does
not affect HESC phenotype
(A) Immunocytochemistry of PB-TET-GFP HESC exposed to 500ng/mL doxycycline for
24 hours express pluripotency markers OCT 3/4, NANOG and SSEA3 (n=4), scale bars
200pM. (B) SYBR-based RT-PCR analysis of gene expression in 4 pluripotent cell lines
treated with 0 and 500ng/mL doxycycline. Gene expression was normalized to TBP and
expressed relative to untreated CA1 HESC. There was no significant difference in OCT4,
NANOG or SOX2 gene expression between HESC treated with doxycycline and
untreated CA1 HESC (n=4, p>0.05).
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was no significant difference between treated and untreated HESC for the expression of
markers of the pluripotent state.

We therefore concluded that the dose of doxycycline

used in these studies, 500ng/mL, does not alter the HESC phenotype.
3.15 Characterization of double transgenic HESC with inducible SOX17 and PDX1.
Following the characterization of cells that allow for inducible SOX 17 activity,
we required a second inducible system to deliver pancreatic transcription factor
expression and further differentiate cells to pancreatic endocrine progenitors.

Having

established the efficacy of the piggyBac system in HESC, we proceeded with the
introduction of PDX1 into SOX17-ER ER r2 HESC. The presence of the PB-TET-PDX1
plasmid was verified by both LacZ staining and genomic PCR following doxycycline
induction (Figure 3.15A-B). Preliminary characterization of clonal cell lines was
performed by treating HESC with either 4-OH Tamoxifen or doxycycline for two days.
Gene expression was assayed for SOX 17 and PDX1 in each clone, and compared to gene
expression levels in human fetal pancreas RNA (obtained commercially from Invitrogen)
(Figure 3.15C). Two clones were identified that had SOX17 gene expression and PDX1
gene expression higher than in human fetal pancreas.

Figure 3.15 Characterization of double transgenic HESC with inducible SOX17 and
PDX1
(A) P-galactosidase staining in clonal populations (W, CC, C, R) of CA1 SOX17-ER12
PB-TET-PDX1 HESC after 2 days of doxycycline treatment (500ng/mL). P-galactosidase
is expressed from the IRES-Pgeo portion o f the PB-TET expression construct. Positive
staining indicates that the PB-TET plasmid has integrated into the genome and is being
actively expressed. (B) Genotyping of genomic DNA extractions from double transgenic
cell lines confirms the presence of the Pgeo element. (C) SYBR-based RT-PCR analysis
of a representative double transgenic cell line used to quantify expression levels o f PDX1.
Cells were untreated (U/T), or treated with either 0.1 pM Tamoxifen (TAM) or 500ng/mL
doxycycline (DOX), or both for 2 days. Gene expression normalized to TBP, expressed
relative to CA1 HESC and compared to levels in human fetal pancreas (HFP).
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4.1 Summary of Results
Pluripotent HESC are capable of differentiation into all 220 cell types present in
the human body, providing tremendous potential for application in cell-based therapies.
Diabetes mellitus is becoming increasingly prevalent in North America, highlighting the
necessity to create a renewable source of pancreatic (3-cells for therapeutic purposes. To
date, differentiation strategies to generate pancreatic endocrine cells from various starting
cell populations including HESC, pancreatic exocrine cells, and pancreatic ductal cells
have generated small clusters of non-proliferative endocrine cells, of which only a small
proportion are functional (Bernardo et al., 2009; Blyszczuk et al., 2003; Collombat et al.,
2009; D'Amour et ah, 2006; Heremans et ah, 2002; Jiang et ah, 2007a; Jiang et ah,
2007b; Kawasaki et ah, 2008; Kroon et ah, 2008; Kubo et ah, 2011; Lavon et ah, 2006;
Liew et ah, 2008; Lin et ah, 2007; Minami et ah, 2005; Miyazaki et ah, 2004; Nostro et
ah, 2011; Serafimidis et ah, 2008; Shim et ah, 2007; Thorel et ah, 2010; Zhou et ah,
2008). Therefore, there is a need to develop alternate strategies by which pancreatic
endocrine cells can be obtained to satisfy the large number of cells required to restore
insulin secretion in response to physiological stimuli as per the Edmonton Protocol
(Shapiro et ah, 2000).
The current study was undertaken to explore the hypothesis that ectopic
expression of lineage-determining transcription factors could be used to generate a source
of proliferative, homogenous pancreatic progenitor cells capable of subsequent
differentiation to functional endocrine cell types, including (3-cells. Recent studies have
shown that functional hepatocytes can be generated using inducible expression of SOX17,
HEX and HNF4a, proving that transcription factor mediated differentiation is a viable

101
and successful differentiation strategy (Takayama et al., 2011).

To address our

hypothesis, transgenic cell lines were generated from both HESC and definitive endoderm
cells (SOX17) that constitutively expressed the pancreatic transcription factors PAX4,
PDX1 or NGN3. Populations were analyzed for gene expression and compared to
standard growth factor-mediated protocols for HESC pancreatic differentiation. Given
the ability of transcription factor expression to drive HESC differentiation, this strategy
was further elaborated using transgenic strategies to confer inducible gene expression in
HESC thereby better recapitulating the patterns of expression seen during embryonic
development. As such, HESC with inducible activity of SOX17, as well as transgenic
HESC with inducible activity of both SOX17 and PDX1 were generated and
characterized.
We present evidence that ectopic expression of PAX4 is not sufficient to specify
pancreatic cells from HESC or DE. PDX1 expression in DE promoted the expression of
insulin, however did not induce the expression of any additional markers of endocrine
differentiation.

In contrast, we observed that expression of NGN3 could specify

pancreatic endocrine cells from DE, as evidenced by the trend towards step wise
induction of markers of endocrine specification (Figure 4.1).

Furthermore, we

demonstrated that HESC adopt a DE phenotype within 4 days of SOX17 activation.
Lastly, we characterized the efficacy of the piggyBac transposon system for gene delivery
in HESC and used this system to generate clonal double transgenic cell lines with
inducible activation of both SOX17 and PDX1.

Figure 4.1 Schematic representation of our findings in relation to pancreatic
differentiation
This study used a transcription factor based approach for the differentiation of
pancreatic endocrine progenitors from HESC. Pancreatic differentiation requires the
initial specification of DE prior to downstream differentiation. We demonstrated that
differentiation of DE from HESC requires 4 days of SOX17 activation. Following DE
specification, constitutive expression of NGN3 generates pancreatic endocrine
progenitor-like cells after 16 days o f differentiation. Furthermore, we demonstrated that
constitutive expression of PDX1 generates insulin positive cells following 16 days of
differentiation, however these cells do not express any additional markers of pancreatic
development as indicated by the dotted line, therefore their status as (3-cells remains to be
determined.
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4.1.1 Contribution o f PAX4 expression to HESC differentiation
PAX4 is a transcription factor required for P-cell specification (Sosa-Pineda et al.,
1997).

Therefore, we hypothesized that ectopic PAX4 expression could promote

differentiation of endocrine progenitors from pluripotent HESC and DE cells. However,
gene expression analysis of PAX4 over-expressing transgenic cell populations in both
CA2 HESC and DE cells revealed no significant induction of any pancreatic, mesodermal
or ectodermal markers (Figure 4.1.1).
Previous studies have shown that over-expression of Pax4 in mouse P-cells in vivo
has

a preventative effect against streptozotocin-induced hyperglycemia due to

suppression of interleukin ip and cytochrome C (Hu He et ah, 2011; Lu et al., 2007).
Additionally, in the neonatal rat pancreas, streptozotocin treatment induces Pax4 and
Ngn3 expression in a-cells, resulting in dedifferentiation to endocrine progenitor cells that
can contribute to pancreatic remodeling (Liang et al„ 2011). In rat pancreatic P-cells,
adenoviral-mediated expression of Pax4 in vitro increased cell proliferation (Brun et al.,
2004). This correlated with induction of c-myc, a cell cycle regulator. Notably, though
PAX4 has been implicated in the suppression of insulin and glucagon gene expression
(Campbell et ah, 1999), however the previously described method of overexpression does
not inhibit pancreatic hormone gene expression. Pax4 expression in mouse pancreatic
epithelium and endocrine tissue resulted in death of the animals by 12 weeks due to
progressive hyperglycemia (Collombat et ah, 2009). This study also demonstrated the
ability of Pax4 expression to drive a-cells to a P-cell fate by generating transgenic mice
that constitutively expressed Pax4 in a-cells.

Within 1 week after birth, these mice
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displayed a 77% decrease in a-cell mass, and an increase in Pax4 positive, insulin
positive cells that express (3-cell markers Nkx6.1, Pdxl and Glut2.
The above-mentioned studies demonstrate a role for Pax4 in late stage (3-cell
development and transdifferentiation of a-cells to P-cells in both rats and mice. Each of
these studies induced Pax4 expression in terminally differentiated cells, which is in
contrast to our study which examined the effects of PAX4 expression in HESC-derived
multipotent progenitors (Seguin et al., 2008).

This may suggest that PAX4 requires

binding partners and cofactors in order to be active that are not present prior to pancreatic
cell specification. Additionally, PAX4 has been implicated as a transcriptional repressor
of pancreatic hormones until the secondary transition at E13.5 (Smith et al., 1999).
During development, PAX4 is expressed to specify P- and 8-cells, but is not expressed in
the mature pancreas (Dohrmann et al., 2000). It is possible that constitutive expression of
this transcriptional repressor in early cell types does not allow for differentiation to a
pancreatic endocrine fate because it inhibits pancreatic hormone gene expression.
Transgenic mouse ES cells with constitutive Pax4 overexpression cultured in
embryoid bodies generate approximately 60% cells with a P-cell like phenotype, with the
remaining cells differentiating into a-cells (Blyszczuk et al., 2003). Additionally, mouse
ES cells subjected to embryoid body-mediated cell differentiation to specify a
mesendodermal progenitor prior to Pax4 nucleofection display expression of pancreatic
endocrine markers Pdxl, somatostatin and produce insulin (Lin et al., 2007). In HESC,
constitutive PAX4 overexpression during embryoid body differentiation for up to 21 days
resulted in a small percentage of cells adopting a P-cell phenotype measured by

Figure 4.1.1 Contribution of PAX4 expression to directed cell differentiation
Schematic representation and summary o f results obtained from PAX4 overexpressing
cells.

PAX4 expression does not induce any pancreatic, mesodermal or ectodermal

markers in CA2 HESC or DE cells.
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expression of Pdxl and insulin, in addition to release of C-peptide in response to
tolbutamide (Liew et al., 2008).
Common to all of these studies is the combination of embryoid body-mediated
differentiation with ectopic expression of Pax4. HESC require initial DE specification
prior to further pancreatic differentiation (Wells and Melton, 1999). The above described
studies have all relied on spontaneous embryoid body differentiation to specify definitive
endoderm, however not all cells within the embryoid body will become DE, and therefore
not all cells will be primed for differentiation to a pancreatic fate.

Our study uses

constitutive expression of SOX 17 in HESC in monolayer culture to specify a
homogeneous population of DE prior to the introduction of PAX4 for further
differentiation. While previous studies have noted differentiation to a (3-cell fate, our
study does not observe any pancreatic differentiation. Though HESC with constitutive
expression of SOX 17 are able to differentiate to a pancreatic fate using growth-factor
mediated protocols (Seguin et al., 2008), it is possible that constitutive expression of
SOX 17 could be preventing PAX4 from functioning appropriately in this context
preventing transcription of its downstream targets. Additionally, by not culturing our
HESC in embryoid bodies, we may be preventing cell-cell context that recapitulates how
these cells differentiate in vivo.

4.1.2 Contribution o fPD Xl expression to HESC differentiation
PDX1 is considered the master regulator of pancreatic development, as all
pancreatic cells are derived from Pdxl positive progenitors (Gu et al., 2003). For this
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reason, we assessed the ability of ectopic expression of PDX1 in pluripotent HESC and
DE cells to specify the pancreatic endocrine fate. Our studies demonstrate that delivery of
PDX1 in DE cells induced a significant upregulation of insulin gene expression within 16
days, however these cells did not demonstrate the induction of any other markers of
pancreatic specification (Figure 4.1.2).
Previous studies have demonstrated that inducible expression of Pdxl in mouse
ES cells induces insulin gene expression when transgenic cells are cultured in embryoid
bodies and first exposed to Activin A for endodermal differentiation, followed by Pdxl
activation (Kubo et al., 2011).

In rat mesenchymal stem cells, Pdxl overexpression

reportedly resulted in insulin positive cells, however insulin was only at low levels (Yuan
et al., 2010).

Both of these studies are limited in their interpretation since cell

differentiation was only assessed by measuring insulin gene expression, and therefore it is
not clear if resultant cells also expressed other markers of pancreatic development. In
contrast, PDX1 overexpression in human bone marrow derived mesenchymal stromal
cells induces expression of various pancreatic endocrine markers including Pax4, Pax6,
NeuroDl and Glut2 with some cells co-expressing insulin and c-peptide, however these
cells did not secrete insulin at biologically significant levels (Limbert et al., 2011).
Additionally, HESC with constitutive expression of PDX1 subjected to differentiation in
embryoid bodies express pancreatic lineage markers such as Pax4, Ngn3 and Nkx2.2,
however did not express insulin or glucagon following 30 days of differentiation in vitro
(Lavon et al., 2006).

Following transplantation of transgenic HESC into the kidney

capsule of immunocompromised mice and subsequent differentition for 1 month, Pdxl

Figure 4.1.2: Contribution of PDX1 expression to directed cell differentiation
Schematic representation and summary o f results obtained from PDX1 overexpressing
cells. Ectopic PDX1 expression in CA2 HESC induces significant induction o f markers
of several lineages.

This induction of early and late markers at the same timepoint

suggests that there is a mixed population. In DE cells, ectopic PDX1 expression induces
late pancreatic endocrine markers by 4 days without the induction of any other pancreatic
lineage markers.

By day 16, these cells have significant insulin gene expression,

suggesting that these are insulin producing cells. (* significantly induced)
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expressing cells expressed insulin mRNA, while non-transgenic HESC did not. These
results suggest that differentiation of P d xl-expressing HESC to a pancreatic endocrine
fate requires signals present in the in vivo microenvironment.

This requirement for

appropriate in vivo microenvironment was also reported with mouse adipose tissuederived stem cells engineered to express Pdxl\ these cells did not express any pancreatic
markers in vitro, however when injected into the tail vein of streptozotocin treated mice,
these cells were able to correct hyperglycemia in 20% of transplanted animals (Kajiyama
et al., 2010).
During embryonic development, expression of Pdxl following endocrine
commitment results in an increase in pancreatic p-cells and a decrease in a-cells (Yang et
al., 2011). Furthermore, when Pdxl was expressed in embryonic and adult a-cells in
vivo, there was a reduction in cells that expressed glucagon; however, only a small
proportion of cells that lost glucagon expression gained insulin expression, suggesting
that transdifferentiation was not efficient.

In mouse and human ES cell-derived

endoderm, biphasic induction of Pdxl expression promoted 30% of cells to adopt an
endocrine cell fate (Bernardo et al., 2009).

The resultant cells, however, expressed

multiple islet hormones. Transdifferentiation of mouse pancreatic exocrine cells to cells
that resemble P-cells has been demonstrated following co-expression of Pdxl, Ngn3 and
MafA (Zhou et al., 2008). However, the efficiency of transdifferentiation was reported at
only 20%.
It is important to note that while these studies have all reported the upregulation of
insulin gene expression following ectopic PDX1 expression, only a subset of these studies
also report the induction of pancreatic markers such as NGN3, NKX2.2 and during
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differentiation (Lavon et al., 2006; Limbert et al., 2011). While our data demonstrate that
constitutive PDX1 expression in DE cells induces insulin gene expression, we did not
demonstrate induction of any additional genes involved in pancreatic development.
PDX1 is a known regulator of insulin gene expression, occupying three different
regions in the human insulin promoter and two regions in the mouse insulin promoter
(Melloul et al., 2002). This is an important consideration in studies where insulin gene
expression is reported as a marker P-cell differentiation without examining a broader
panel of markers of different stages of pancreatic development to assess if cells are
following the appropriate developmental pattern. It is possible that many of these studies
have generated insulin producing cells, but not cells that have a functional P-cell
phenotype.

This may explain why the majority of these studies produce cells with

minimal or no response to physiological glucose stimulation.
Interestingly, when PDX1 was constitutively expressed in pluripotent HESC, we
observed induction of neurectodermal and mesendodermal markers. It has been shown in
mouse ES cells that markers of pancreatic differentiation Pdxl, Ngn3, and Pax6 are
expressed in ES-cell derived ectodermal cells (Roche et al., 2005). These ectodermal
cells do not express insulin mRNA unless cultured in media conditioned by the rat
insulinoma cell line INS-1. This is concurrent with our data where ectodermal markers
SOX3 and NESTIN were upregulated during the early stages of PDX1-mediated
differentiation

during

our

differentiation

process,

suggesting

some

degree

of

neurectodermal differentiation. This demonstrates the importance of cell context prior to
transcription factor introduction since DE cells are not competent to undergo ectodermal
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differentiation and therefore show no induction of neural markers following PDX1
expression.
Analysis of transgene expression levels in SOX17 PDX1 HESC revealed
considerable variation between transgenic populations.

Population A demonstrated

100,000 fold increase in PDX1 expression vs undifferentiated controls at day 4, while
population B had 1,200 fold induction and population C had a 4100 fold induction.
Additionally, population A and C showed trends towards decreasing PDX1 expression
over the time course, while population B demonstrated the opposite trend of increasing
PDX1 expression. The inherent variation in transgene expression levels is likely due to
both the number of integration events and the genomic site of PDX1 transgene insertion.
Since the piggyBac system allows for transgene insertion at any TTAA site in the
genome, it is possible that some copies of the transgene were inserted into
heterochromatin and are therefore not actively expressed. Additionally, insertion site is
important for the plasmid that confers rtTA expression, as this protein is required for
PDX1 transcription. Some populations may have more rtTA expression, and therefore
more protein for doxycycline to bind to, resulting in increased transgene expression.
Importantly, these variations in PDX1 expression may have an effect on the resultant
gene expression patterns in these cells in addition to cell morphology. Transgenic cell
populations with higher PDX1 transgene expression may upregulate downstream PDX1
targets that populations with lower PDX1 gene expression do not.

Specifically,

transgenic population A which demonstrated a 100,000 fold upregulation of PDX1
transgene expression vs undifferentiated HESC may have overwhelmed the cell’s
transcriptional machinery and prevented any further upregulation of gene expression.
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4.1.3 Contribution ofNGN3 expression to directed cell differentiation
All pancreatic endocrine cells are derived from NGN3 positive progenitors
(Jensen et al., 2000; Smith et al., 2004).

Because of this, we hypothesized that

constitutive expression of NGN3 could be used to generate pancreatic endocrine cells
from DE cells. Ectopic NGN3 expression in DE cells resulted in an obvious change in
cell morphology, increasing the cytoplasmic to nuclear ratio and promoting the
accumulation of cytoplasmic vacuoles after 8 days of differentiation. The presence of
cytoplasmic vacuoles suggests there is active endo- or exocytosis activities within in these
cells (Burgoyne and Morgan, 2003). These cytoplasmic vacuoles have the potential to be
insulin secretory granules (Russ et al., 2011), as insulin gene expression shows a trend
towards upregulation at this time point. Further analysis by both immunocytochemistry
and scanning electron microscope (SEM) would be required to characterize these
subcellular structures.
Through gene expression analysis, we also demonstrate a trend toward initiation
of a transcriptional cascade associated with pancreatic development that involved
downregulation of DE markers and upregulation of PAX4, PAX6, PDX1, NKX2.2,
NKX6.1 and INS (Figure 4.1.3). These genes were activated in a sequential manner that
mimicked biological pancreatic endocrine cell development, presumably due to the
presence of an appropriate DE context prior to NGN3 expression. Though we observed
sequential gene activation, we are assuming that this is occurring within the same cell
population. However, we acknowledge that since this analysis was done at the population
level, different cells within the population may be expressing subsets of these markers.
Our findings correlate with previous studies of where NGN3 expression in

Figure 4.1.3: Contribution of NGN3 expression to directed cell differentiation
Schematic representation and summary o f results obtained from NGN3 overexpressing
cells. In CA2 HESC, ectopic expression o f NGN3 induces markers o f DE, late pancreatic
markers, as well as pancreatic exocrine markers at day 4. Ectopic expression o f NGN3 in
DE cells induces a cascade of pancreatic markers that are expressed in a sequential order
mimicking pancreatic development. These genes demonstrated a trend toward increased
gene expression, however did not reach significace. (* significantly induced)
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progenitor cell types was shown to initiate expression of factors associated with the
endocrine differentiation cascade (Gasa et al., 2004; Grapin-Botton et al., 2001;
Heremans et al., 2002; Kubo et al., 2011; Lee et al., 2001; Limbert et al., 2011).
Interestingly, although NGN3 positive progenitors were capable of generating all
endocrine cell types during development, in our studies constitutive expression of NGN3
in DE cells did not induce GCG or SST gene expression, suggesting the absence of a- or
8- cell differentiation. These findings further suggest the induction of developmentally
relevant endocrine cell differentiation using NGN3 expression since the resulting cell
types do not demonstrate co-expression of multiple hormone mRNAs as reported in
previous studies (Katsuta et al., 2010; Thorel et al., 2010).
Co-expression of Ngn3 and Pdxl in mouse ES-cell derived endoderm has been
shown to induce the expression of pancreatic markers and promote insulin secretion. The
resultant cells were not responsive to glucose, suggesting they are an immature form of
pancreatic endocrine cells (Kubo et al., 2011). Ectopic NGN3 expression in human bone
marrow derived mesenchymal stromal cells induced pancreatic gene expression, and 25%
of cells were insulin positive, however insulin production was not significant (Limbert et
al., 2011). Combined delivery of Pdxl and Ngn3 in mouse liver in vivo has been shown
to induce insulin gene expression (Kaneto et al., 2005). Taken together, these studies
demonstrate that co-expression of PDX1 and NGN3 can generate immature pancreatic
cells.

An alternative to simultaneous expression of both of these transcription is

sequential activation.

We have demonstrated that following SOX17-mediated DE

specification, activation of NGN3 can specify endocrine progenitors. It is possible that
subsequent expression of PDX1 in these cells could generate functional pancreatic cells.
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4.1.4 Comparison o f transcription factor- and growth factor- mediated pancreatic
endocrine differentiation
Early studies using HESC to generate pancreatic cell types in vitro established that
the generation of pancreatic precursor cells requires the initial specification of DE
(D'Amour et al., 2006). To date this has been accomplished using various methods to
generate DE from HESC such as activin A-mediated growth factor differentiation
(D'Amour et al., 2005), as well as embryoid body formation (Liew et al., 2008). Activin
A is known to induce DE differentiation in vertebrates, (Stainier, 2002); however, is only
80% efficient in specifying DE from HESC (D'Amour et al., 2005).

Conversely,

culturing HESC in EBs results in spontaneous differentiation to all 3 primary germ layers
and therefore has a lower efficiency than activin A-mediated differentiation. In general,
these protocols results in the production of a heterogeneous population of cells, thereby
limiting the number of cells that can go on to become pancreatic endocrine cells.
Furthermore, while generation of DE using Activin A is more efficient than spontaneous
EB differentiation, cell proliferation has been shown to be dramatically reduced with the
onset of differentiation, thereby increasing the number of cells required for long-term
differentiation.

Alternatively, lineage-committed DE cells have been generated through

constitutive expression of SOX17 in HESC (Seguin et al., 2008).

This results in a

homogeneous, proliferative population of cells receptive to signals for further
differentiation to a variety of mature endoderm cell types including pancreatic cells.
Following DE specification, several strategies have been elucidated for the
generation of P-cells. Stepwise protocols have been developed using sequential addition
of developmentally relevant growth factors over long term in vitro culture to generate
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pancreatic p-cells (D'Amour et al., 2006; Jiang et al., 2007a; Jiang et al., 2007b; Nostro et
al., 2011; Shim et al., 2007).

Although these methods have been extensively

characterized, they have limitations that are undesirable.

These protocols produce a

population of cells in which the P-cell phenotype comprises less than 15% of the final
population (D'Amour et al., 2005).

Researchers have optimized these growth factor-

mediated approaches by manipulating key pathways in P-cell development, however
despite these efforts the resultant populations contained only 25% C-peptide positive cells
(Nostro et al., 2011). Alternatively, pancreatic exocrine cells have been transdifferentiated
into pancreatic endocrine cells by in vivo viral-mediated gene delivery of the transcription
factors MafA, Pdxl and Ngn3 (Zhou et al., 2008). The initial population of pancreatic
exocrine cells is not self-renewable and the efficiency of transdifferentiation was only
20% (Zhou et al., 2008). Previous studies have also described the ectopic expression of
the transcription factors PDX1 (Kawasaki et al., 2008; Kubo et al., 2011; Lavon et al.,
2006; Limbert et al., 2011; Miyazaki et al., 2004), NGN3 (Kubo et al., 2011; Limbert et
al., 2011; Serafimidis et al., 2008) and PAX4 (Blyszczuk et al., 2003; Liew et al., 2008)
in various cell types including pancreatic ductal cells, pancreatic exocrine cells, and ESderived endoderm cells in efforts to generate pancreatic endocrine cells.

4.1.5. Generation o f definitive endoderm through transient expression ofSOX17
Previous data has demonstrated that constitutive expression of SOX17 in HESC is
sufficient to generate DE (Seguin et al., 2008). Additionally, it is known that during
murine development Sox 17 is expressed concurrent with DE formation and is
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downregulated upon DE specification (Kanai-Azuma et al., 2002). Therefore, this study
sought to characterize HESC with inducible activation of SOX17 in order to better mimic
developmental patterns.
induction, SOX17-ER

We present data demonstrating that following 4 days of
HESC adapt a DE phenotype, with significant expression of DE

markers CER1, CXCR4 and DLX5. The timeframe of 4 days to specify DE from HESC
is markedly shorter than 16 days to specify DE from the inner cell mass in a developing
embryo. This may be due to the levels of SOX17 in the transgenic HESC, in addition to
the monolayer culture that the cells are grown in permitting 4-OH Tamoxifen to bind to
every cell resulting in subsequent differentiation. However, our current studies do not
determine if 4 days of SOX 17 expression is sufficient to irreversibly commit HESC to the
DE lineage.

To determine if cells are committed, the transgene would have to be

removed and cell potential analyzed following transgene removal. Additionally, previous
reports of HESC with constitutive SOX17 expression were shown to demonstrate a
mesendodermal phenotype, generating both mesoderm and endoderm tissue in a teratoma
assay (Seguin et al., 2008). To determine if DE cells generated from transient SOX17
activity are committed to the endoderm lineage, or if they adopt a mesendodermal
phenotype like the HESC with constitutive expression of SOX17, a teratoma assay would
have to be performed.
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4.1.6 Characterization o f the piggyBac transposase system in HESC and generation o f
double transgenic HESC fo r pancreatic endocrine differentiation
The piggyBac transposase system used in these studies is a tet-inducible system
for transient and reversible transgene delivery in mammalian cells (Ding et al., 2005).
This system has been used to express c-Myc, Klf4, Sox2 and Oct4 to reprogram mouse
fibroblasts to induced pluripotent stem cells (Woltjen et al., 2009). Through generation of
PB-TET-GFP HESC, we determined that 500ng/mL doxycycline maximally induces
transgene activity without affecting cell phenotype. Doses of doxycycline greater than
500ng/mL may be cytotoxic to the cells, which could account for decreased gene
expression. The piggyBac system is unique, as it allows for complete transgene removal,
leaving no genetic footprint.

Additionally, this inducible transgenic system does not

require the generation of a fusion protein that could potentially affect gene function.
Once we characterized a second drug-inducible gene delivery system, we
generated double transgenic HESC that had inducible expression of SOX 17 and PDX1.
Expression of both SOX17 and PDX1 during embryonic development follow biphasic
patterns of induction (Hui and Perfetti, 2002; Kanai-Azuma et al., 2002; Offield et al.,
1996), therefore an inducible model will allow us to better recapitulate developmental
patterns of gene expression. We found clonal, double transgenic populations that express
PDX1 at the level of, or greater than, human fetal pancreas.
4.2 Limitations of Research
For this study, we assayed the ability of three pancreatic transcription factors to
drive specification of pancreatic endocrine cells from pluripotent cells, as well as cells
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that are committed to the definitive endoderm lineage.

To do this, we generated

transgenic cell populations through electroporation-mediated plasmid delivery and
observed changes at the population level. Population analysis allowed us to develop a
protocol for rapid, high throughput screening to assay the ability of individual pancreatic
transcription factors to specify pancreatic endocrine cells but real-time PCR.

One

important limitation to this approach is that analysis was not conducted clonal cell
populations. Consequently, all phenotypic analysis was conducted on a mixed population
of cells due to factors such as the variation in the number of transgene integration events
in each cell, as well as cell-cell communication within a heterogeneous population.
Furthermore, given the disparity between transgene expression levels across the
population, we cannot assume that differentiation was homogeneous.

Furthermore,

during development, pancreatic genes are temporally regulated, and disruption of this
regulation can cause adverse effects. Constitutive expression of SOX17 to generate DE,
followed by constitutive PAX4, PDX1 or NGN3 expression is an effective method for
initial screening of these pancreatic genes, however it limits the ability to recapitulate
complex and temporal developmental patterns of transcription factor activity.
The primary method used in these studies for characterization of novel transgenic
HESC lines was quantitative gene expression analysis. This provided us with the ability
to screen for markers of multiple lineages in a high-throughput manner.

However,

mRNA transcript levels do not always accurately reflect cellular protein levels due to
post-transcriptional and translational regulation.

In order to validate the changes in

mRNA expression observed, functional analysis should be undertaken by immunoblotting
or immunocytochemistry for markers such as insulin, glucagon and somatostatin.

In
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addition, immunocytochemistry should be performed for the products of the transgenes
PDX1, NGN3 and PAX4 to ensure that they are being translated into protein, and that the
protein is localized to the nucleus for functional downstream transcriptional regulation.

4.3 Future Directions
The current studies present preliminary but promising evidence supporting the
hypothesis that transcription factor expression can be used to efficiently direct the
differentiation of HESC to a pancreatic endocrine phenotype. To further this study, I
would generate clonal populations of HESC with inducible SOX17 activity using the
ER12 system (Hayashi and McMahon, 2002) and NGN3 activity through the use of the
piggyBac transposase system (Woltjen et al., 2009). This would allow for control of dose
and duration of both definitive endoderm and pancreatic transcription factor activity.
Following the generation of these transgenic HESC, I would perform
differentiation experiments maintaining cells in both monolayer culture and 3D culture
using embryonic bodies (EB). The use of an EB system may better recapitulate cell-cell
contact during development thereby enabling a more developmentally relevant context.
Real-time

PCR

would

be

performed

to

assay

gene

expression,

while

immunocytochemistry would be performed for transgenes in addition to pancreatic
hormones INS, GCG and SST.

To determine the efficiency of differentiation, flow

cytometry would be performed. Once a homogeneous population of pancreatic endocrine
cells is generated, I would perform a teratoma assay to assess if the cells are committed to
the pancreatic endocrine lineage.
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Once a source of pancreatic progenitors is obtained, I would transplant them into
the tail vein in a mouse model of diabetes and track cell migration to see if these cells are
functional and correct hyperglycemia.

Injection in the tail vein allows access to

vasculature and the cells are able to migrate to multiple tissues. A common problem with
transplantation is the endogenous immune response that will destroy the transplanted
cells.

Commonly, cells are transplanted in immuno-compromised mice to avoid this

problem. Alternatively, cells could be coated in alginate (Tuch et al., 2011), a semi
permeable material that will allow for insulin to pass through, but prevent immune cells
from destroying cell transplants. Polyethylene glycol coatings have also been studied as a
method for delivering islet cells (Kizilel et al., 2010). Interestingly, cells encapsulated
with polyethylene glycol can secrete more insulin compared to control islets.
Lastly, I would determine if the transplanted cells end up in the pancreas, or if
they migrate to alternative tissues.

To do this, I would label the cells with iron

nanoparticles so that the animals could be live-imaged using MRI techniques (Tai et al.,
2006). It is known that iron nanoparticles do not affect functionality of islet cells (Kim et
al., 2009).
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